US20100048495A1 - Core 2 GlcNAc-T inhibitors III - Google Patents
Core 2 GlcNAc-T inhibitors III Download PDFInfo
- Publication number
- US20100048495A1 US20100048495A1 US12/588,606 US58860609A US2010048495A1 US 20100048495 A1 US20100048495 A1 US 20100048495A1 US 58860609 A US58860609 A US 58860609A US 2010048495 A1 US2010048495 A1 US 2010048495A1
- Authority
- US
- United States
- Prior art keywords
- sac
- alkyl
- food
- beverage product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1C(OC)OC([4*])C([3*])C1[2*] Chemical compound [1*]C1C(OC)OC([4*])C([3*])C1[2*] 0.000 description 14
- UACIBCPNAKBWHX-UHFFFAOYSA-N C1CCC2C(C1)CCC1C3CCCC3CCC21 Chemical compound C1CCC2C(C1)CCC1C3CCCC3CCC21 UACIBCPNAKBWHX-UHFFFAOYSA-N 0.000 description 1
- PFBWISZEYPUNFR-ZUOVRASVSA-N C=C1CCC2(OC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CC[C@@]2(C)C(=CCC3C2CC[C@]2(C)C4C(CC32O)OC2(CC(O)C(C)CO2)[C@H]4C)C1.CC1CC[C@@]2(C)C(=CCC3C4CC5OC6(CC(O)C(C)CO6)[C@@H](C)C5(O)[C@@]4(C)CCC32)C1.CC1CC[C@@]2(C)C(=CCC3C4CC5OC6(CCC(CO)CO6)[C@@H](C)C5[C@@]4(C)CCC32)C1.CC1CC[C@@]2(C)C(=CCC3C4CC5OC6(CCC(COC(=O)[C@](C)(O)CC(=O)O)CO6)[C@@H](C)C5[C@@]4(C)CCC32)C1 Chemical compound C=C1CCC2(OC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CC[C@@]2(C)C(=CCC3C2CC[C@]2(C)C4C(CC32O)OC2(CC(O)C(C)CO2)[C@H]4C)C1.CC1CC[C@@]2(C)C(=CCC3C4CC5OC6(CC(O)C(C)CO6)[C@@H](C)C5(O)[C@@]4(C)CCC32)C1.CC1CC[C@@]2(C)C(=CCC3C4CC5OC6(CCC(CO)CO6)[C@@H](C)C5[C@@]4(C)CCC32)C1.CC1CC[C@@]2(C)C(=CCC3C4CC5OC6(CCC(COC(=O)[C@](C)(O)CC(=O)O)CO6)[C@@H](C)C5[C@@]4(C)CCC32)C1 PFBWISZEYPUNFR-ZUOVRASVSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N CC Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- ZWUUYJSRYMSXJG-ZETCQYMHSA-N CC(=O)C[C@](C)(O)CC(=O)O Chemical compound CC(=O)C[C@](C)(O)CC(=O)O ZWUUYJSRYMSXJG-ZETCQYMHSA-N 0.000 description 1
- GYEHQGFTBVMLFZ-UHFFFAOYSA-N CC(C)=CC1CC(C)(O)C2C3CCC4C5(C)CCC(C)C(C)(C)C5CCC4(C)C34CCC2(C4)O1.CC(C)=CCC1OC23CCC4(C2)C(C)(CCC2C5(C)CCC(C)C(C)(C)C5CCC24C)C3C1(C)O.CCC(C)CCC1(O)OC2CC3C4CCC5CC(C)CCC5(C)C4CCC3(C)C2C1C.[H]C12CCC3C4(C)CCC(C)C(C)(C)C4CCC3(C)C1(O)C(O)C1(O)OC(CC=C(C)C)C(C)(O)C12 Chemical compound CC(C)=CC1CC(C)(O)C2C3CCC4C5(C)CCC(C)C(C)(C)C5CCC4(C)C34CCC2(C4)O1.CC(C)=CCC1OC23CCC4(C2)C(C)(CCC2C5(C)CCC(C)C(C)(C)C5CCC24C)C3C1(C)O.CCC(C)CCC1(O)OC2CC3C4CCC5CC(C)CCC5(C)C4CCC3(C)C2C1C.[H]C12CCC3C4(C)CCC(C)C(C)(C)C4CCC3(C)C1(O)C(O)C1(O)OC(CC=C(C)C)C(C)(O)C12 GYEHQGFTBVMLFZ-UHFFFAOYSA-N 0.000 description 1
- OFXUJPBPMNXXIB-MTJPXAOOSA-N CC1CCC2(C)C(=CCC3C2CCC2(C)C3CC3C2[C@H](C)C2CC[C@H](C)CN32)C1.CC1CCC2(NC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CCC5CC(C)CC[C@]5(C)C4CC(=O)[C@]3(C)C1[C@@H]2C.COCC1(C)COC2(C1)OC1CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C1C2C Chemical compound CC1CCC2(C)C(=CCC3C2CCC2(C)C3CC3C2[C@H](C)C2CC[C@H](C)CN32)C1.CC1CCC2(NC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CCC5CC(C)CC[C@]5(C)C4CC(=O)[C@]3(C)C1[C@@H]2C.COCC1(C)COC2(C1)OC1CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C1C2C OFXUJPBPMNXXIB-MTJPXAOOSA-N 0.000 description 1
- YCTVZTGQHOFHAP-UHFFFAOYSA-N CC1CCC2(C)C(CCC3(C)C2CC(O)C2C(C4(C)CC(O)C(C(C)(C)O)O4)CCC23C)C1(C)C.CC1CCC2(C)C(CCC3(C)C2CC(O)C2C(C4(C)CC(O)C(C(C)(C)O)O4)CCC23C)C1(C)CO.CCC(CCC(C)C1CCC2C3CC=C4CC(C)CCC4(C)C3CCC12C)C(C)C.[H]C12CC=C3CC(C)CCC3(C)C1CCC1(C)C(C(C)=O)=CCC12O.[H]C12CCC3C4(C)CCC(C)C(C)(C)C4CCC3(C)C1(C)CCC2C(O)(CC)CCCC=C(C)C Chemical compound CC1CCC2(C)C(CCC3(C)C2CC(O)C2C(C4(C)CC(O)C(C(C)(C)O)O4)CCC23C)C1(C)C.CC1CCC2(C)C(CCC3(C)C2CC(O)C2C(C4(C)CC(O)C(C(C)(C)O)O4)CCC23C)C1(C)CO.CCC(CCC(C)C1CCC2C3CC=C4CC(C)CCC4(C)C3CCC12C)C(C)C.[H]C12CC=C3CC(C)CCC3(C)C1CCC1(C)C(C(C)=O)=CCC12O.[H]C12CCC3C4(C)CCC(C)C(C)(C)C4CCC3(C)C1(C)CCC2C(O)(CC)CCCC=C(C)C YCTVZTGQHOFHAP-UHFFFAOYSA-N 0.000 description 1
- JNSJFSKAGASGQM-JEUJOAMKSA-N CC1CCC2(OC1)OC1CC3(O)C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1(O)[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CCC5CC(C)CC[C@]5(C)C4CC(O)[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CCC5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C Chemical compound CC1CCC2(OC1)OC1CC3(O)C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1(O)[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CC=C5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CCC5CC(C)CC[C@]5(C)C4CC(O)[C@]3(C)C1[C@@H]2C.CC1CCC2(OC1)OC1CC3C4CCC5CC(C)CC[C@]5(C)C4CC[C@]3(C)C1[C@@H]2C JNSJFSKAGASGQM-JEUJOAMKSA-N 0.000 description 1
- JPBFCMGMIINRQP-UHFFFAOYSA-N CC1OC(CO)C(C)C(O)C1C Chemical compound CC1OC(CO)C(C)C(O)C1C JPBFCMGMIINRQP-UHFFFAOYSA-N 0.000 description 1
- QUQSEKHCWKJUPC-MCNLTSEVSA-N CCC(C)CC(C)C1(C)CC2CC3(C)C4CCC5C[C@@H](CC)C(C)C[C@]5(C)C4CC[C@]3(C)C2(C)[C@@H]1C Chemical compound CCC(C)CC(C)C1(C)CC2CC3(C)C4CCC5C[C@@H](CC)C(C)C[C@]5(C)C4CC[C@]3(C)C2(C)[C@@H]1C QUQSEKHCWKJUPC-MCNLTSEVSA-N 0.000 description 1
- UEYPGMNVYMHVPD-UHFFFAOYSA-N CCC(C)CC(OC)C1=C(C)C2C(CC3(O)C4CC=C5CC(C)CCC5(C)C4CCC23C)O1.CCC(C)CCC1(O)OC2CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.CCC(C)CCC1(OC)OC2CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.CCC(C)CCC1=C(C)C2C(CC3(O)C4CC=C5CC(C)CCC5(C)C4CCC23C)O1.CCC(C)CCC1=C(C)C2C(CC3C4CC=C5CC(C)CCC5(C)C4CCC32C)O1 Chemical compound CCC(C)CC(OC)C1=C(C)C2C(CC3(O)C4CC=C5CC(C)CCC5(C)C4CCC23C)O1.CCC(C)CCC1(O)OC2CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.CCC(C)CCC1(OC)OC2CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.CCC(C)CCC1=C(C)C2C(CC3(O)C4CC=C5CC(C)CCC5(C)C4CCC23C)O1.CCC(C)CCC1=C(C)C2C(CC3C4CC=C5CC(C)CCC5(C)C4CCC32C)O1 UEYPGMNVYMHVPD-UHFFFAOYSA-N 0.000 description 1
- KOSDTIJCENZBQV-UHFFFAOYSA-N CCC(C)CCC1(O)OC2CC3(O)C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.CCC(C)CCC1=C(C)C2C(CC3C4CCC5CC(C)C(O)CC5(C)C4CCC32C)O1.COC1(CCC(C)CO)OC2CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.COC1(CCC(C)COC(C)=O)OC2CC3(O)C4CCC5CC(C)CCC5(C)C4CCC3(C)C2(O)C1C.COC1(CCC(C)COC(C)=O)OC2CC3C4CCC5CC(C)CCC5(C)C4CCC3(C)C2(O)C1C Chemical compound CCC(C)CCC1(O)OC2CC3(O)C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.CCC(C)CCC1=C(C)C2C(CC3C4CCC5CC(C)C(O)CC5(C)C4CCC32C)O1.COC1(CCC(C)CO)OC2CC3C4CC=C5CC(C)CCC5(C)C4CCC3(C)C2C1C.COC1(CCC(C)COC(C)=O)OC2CC3(O)C4CCC5CC(C)CCC5(C)C4CCC3(C)C2(O)C1C.COC1(CCC(C)COC(C)=O)OC2CC3C4CCC5CC(C)CCC5(C)C4CCC3(C)C2(O)C1C KOSDTIJCENZBQV-UHFFFAOYSA-N 0.000 description 1
- YSZUKWLZJXGOTF-UHFFFAOYSA-N CCC.CCC Chemical compound CCC.CCC YSZUKWLZJXGOTF-UHFFFAOYSA-N 0.000 description 1
- YQFZBWDORCUSLC-XDCGMBBVSA-N CCC1CC[C@@]2(C)C(=CCC3C4CC5C([C@H](C)C6CC[C@H](C)CN56)[C@@]4(C)CCC32)C1 Chemical compound CCC1CC[C@@]2(C)C(=CCC3C4CC5C([C@H](C)C6CC[C@H](C)CN56)[C@@]4(C)CCC32)C1 YQFZBWDORCUSLC-XDCGMBBVSA-N 0.000 description 1
- KMIQLSCDTYYFLA-FOKHCCBPSA-N CCC1CC[C@@]2(C)C(CCC3C2CC[C@@]2(C)C3CC3O[C@]4(CCC(C)CN4)[C@@H](C)C32)C1 Chemical compound CCC1CC[C@@]2(C)C(CCC3C2CC[C@@]2(C)C3CC3O[C@]4(CCC(C)CN4)[C@@H](C)C32)C1 KMIQLSCDTYYFLA-FOKHCCBPSA-N 0.000 description 1
- GGPVZCWDJVEILU-YLGQNHGPSA-N CC[C@H]1CC[C@@]2(C)C(=CCC3C4CC5OC6(C[C@@](C)(COC)CO6)[C@@H](C)C5[C@@]4(C)CCC32)C1 Chemical compound CC[C@H]1CC[C@@]2(C)C(=CCC3C4CC5OC6(C[C@@](C)(COC)CO6)[C@@H](C)C5[C@@]4(C)CCC32)C1 GGPVZCWDJVEILU-YLGQNHGPSA-N 0.000 description 1
- HLTHDHCKHDEOBY-UPBXAFHZSA-N CC[C@H]1CC[C@@]2(C)C(CCC3C2CC(C)[C@@]2(C)C3(C)CC3OC4(CC(C)C(C)C(C)C4)[C@@H](C)C32C)C1 Chemical compound CC[C@H]1CC[C@@]2(C)C(CCC3C2CC(C)[C@@]2(C)C3(C)CC3OC4(CC(C)C(C)C(C)C4)[C@@H](C)C32C)C1 HLTHDHCKHDEOBY-UPBXAFHZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N COC Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- IJEDIKSWSJHRGM-QMMMGPOBSA-N COC(=O)C[C@@](C)(O)CC(C)=O Chemical compound COC(=O)C[C@@](C)(O)CC(C)=O IJEDIKSWSJHRGM-QMMMGPOBSA-N 0.000 description 1
- KQWGISGHVBOPOX-UHFFFAOYSA-N COCC(COC(CO)C1C2O)(C12O)O Chemical compound COCC(COC(CO)C1C2O)(C12O)O KQWGISGHVBOPOX-UHFFFAOYSA-N 0.000 description 1
- HOVAGTYPODGVJG-XXCPCPGCSA-N [H]C1(OC)OC(CO)C(O)[C@@H](O)[C@@H]1O Chemical compound [H]C1(OC)OC(CO)C(O)[C@@H](O)[C@@H]1O HOVAGTYPODGVJG-XXCPCPGCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention relates to the use of known and novel compounds as pharmaceutical actives against diseases susceptible to treatment by modulation, eg. inhibition, of the enzyme Core 2 GlcNAc-transferase (EC 2.4.1.162), also known as UDP-GlcNAc:Gal ⁇ 1,3GalNAc-R (GlcNAc to GalNAc) ⁇ -1,6-N-acetylglucosaminyl transferase (core 2 ⁇ -1,6 N-acetylaminotransferase, hereinafter referred to as Core 2 GlcNAc-T.
- Core 2 GlcNAc-transferase EC 2.4.1.162
- UDP-GlcNAc:Gal ⁇ 1,3GalNAc-R GlcNAc to GalNAc
- Core 2 ⁇ -1,6 N-acetylaminotransferase hereinafter referred to as Core 2 GlcNAc-T.
- Inhibitors of Core 2 GlcNAc-T have application in therapy for diseases in which core 2 GlcNAc-T is implicated and especially those in which the enzyme activity is raised relative to the normal level in the tissue type concerned, or those conditions in which it is advantageous to lower the activity of core 2 GlcNAc-T for example to its normal level or below.
- Examples of such conditions are inflammatory diseases such as atherosclerosis and multiple sclerosis, diabetes, cancer and its metastasis.
- Inhibitors of Core 2 GlcNAc-T are known but none are in clinical development as isolated actives for pharmaceutical use. Examples of known compounds are disclosed in WO0187548, Kuhns (15), Hindsgaul (45) and Toki (46).
- Applicant's co-pending application WOO5060977 discloses known and novel steroidal glycosides that have therapeutic use as Core GlcNAc-T inhibitors, discusses the basis for use of such inhibitors in therapy and discloses published documents detailing the basis for Core 2 GlcNAc-T involvement in a number of diseases.
- the present application discloses further steroidal glycoside compounds that are suitable for use in therapy for diseases in which Core 2 GlcNAc-T is implicated and additional such conditions in which such compounds have a therapeutic use.
- steroidal glycosides have been tested previously in a limited number of disease paradigms. For example in protection against gastric mucosal lesions in rats (80), in mouse ear edema tests for anti inflammatory activity (79), in treatment of dementia (U.S. Pat. No. 6,593,301) as “immuno-modulators” and spermatogenesis and ovulation stimulators (74) and as adjuvants (75). Compounds of the invention have also been used in cytotoxicity assays (e.g. 36, 40, 72), however cytotoxic concentrations are several orders of magnitude higher than those currently disclosed for inhibition of Core 2 GlcNAc-T activity. None of the aforementioned publications discloses that certain steroidal glycosides are inhibitors of Core 2 GlcNAc-T.
- Certain plant sterol compounds some of which are used as dietary supplements, impede the uptake of cholesterol from the gut and consequently lower plasma LDL cholesterol. However these compounds are generally used in doses of several grams per day and are not known to be inhibitors of Core 2 GlcNAc-T.
- the present invention is provided a method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T, particularly raised activity, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of formula I to a patient in need thereof
- R 1 is H, —OH, C 1-6 alkoxy, —NR 5 R 6 , or Sac 1;
- R 2 is H, —OH, C 1-6 alkoxy or Sac 2;
- R 3 is H, —OH, C 1-6 alkoxy or Sac 3;
- R 4 is H, C 1-6 alkyl, C 1-6 hydroxyalkyl or C 1-6 -alkoxy-C 1-6 -alkyl;
- R 5 is H, C 1-6 alkyl or C 1-6 acyl
- R 6 is H, C 1-6 alkyl or C 1-6 acyl
- Sac 1, Sac 2 and Sac 3 are independently selected saccharide moieties attached to the ring through an oxygen;
- Z is a steroid moiety
- ring A When one of R 1 to R 3 is a saccharide moiety, the ring of formula I is designated ring A.
- R 1 is H, —OH, C 1-6 alkoxy, —NR 5 R 6 , or Sac 1; preferably R 1 is H, —OH, or Sac 1; more preferably R 1 is Sac 1;
- R 2 is H, —OH, C 1-6 alkoxy or Sac 2; preferably R 2 is H, —OH or Sac 2; more preferably R 2 is —OH;
- R 3 is H, —OH, C 1-6 alkoxy or Sac 3; preferably R 3 is H, —OH or Sac 3; more preferably R 3 is Sac 3;
- R 4 is H, C 1-6 alkyl, C 1-6 hydroxyalkyl or C 1-6 -alkoxy-C 1-6 -alkyl; preferably R 4 is H, C 1-6 alkyl or C 1-6 hydroxyalkyl; more preferably R 4 is H, —CH 2 OH or —CH 3 ; more preferably still R 4 is —CH 2 OH; more preferably still R 4 is —CH 2 OH and the resultant moiety is a glucose or galactose moiety; most preferably R 4 is —CH 2 OH and the resultant moiety is a glucose moiety;
- R 5 is H, C 1-6 alkyl or C 1-6 -acyl; preferably R 5 is H or C 1-6 alkyl; more preferably R 5 is H or —CH 3 ; most preferably R 5 is H;
- R 6 is H, C 1-6 alkyl or C 1-6 acyl; preferably R 6 is H—CH 3 or —COCH 3 ; most preferably R 6 is —COCH 3 ; and
- Sac 1, Sac 2 and Sac 3 are saccharide moieties attached to the ring through an oxygen; preferably Sac 1 Sac 2 and Sac 3 are independently selected from monosaccharide moieties and disaccharide moieties; preferably they are monosaccharide moieties; more preferably Sac 1 Sac 2 and Sac 3 are independently selected from a tetrose a pentose and a hexose.
- Sac 1 is selected from a pentose, a deoxy-aldohexose and an aldohexose; more preferably Sac 1 is selected from arabinose, xylose, glucose, mannose, galactose, and a deoxy-aldohexose; more preferably Sac 1 is selected from arabinose, xylose, glucose, mannose, galactose, and a 6-deoxyaldohexose; more preferably Sac 1 is selected from glucose, galactose, arabinose, xylose and rhamnose; most preferably it is rhamnose;
- Sac 2 is selected from a pentose, a deoxy-aldohexose and an aldohexose; more preferably Sac 2 is selected from arabinose, xylose, glucose, mannose, galactose, and a deoxyaldohexose; more preferably Sac 2 is selected from arabinose, xylose, glucose, mannose, galactose, and a 6-deoxyaldohexose; more preferably Sac 2 is selected from. glucose, galactose, arabinose, xylose and rhamnose;
- Sac 3 is selected from a pentose, a deoxy aldohexose and an aldohexose; arabinose, xylose, quinovose rhamnose or an aldohexose, more preferably Sac 3 is selected from arabinose, xylose, quinovose, rhamnose, mannose, glucose and galactose, most preferably Sac 3 is rhamnose or glucose;
- Z is a steroid moiety
- Core 2 GlcNAc-T modulation may be used to treat inter alia, vascular diseases, (including complications of diabetes), autoimmune and inflammatory conditions.
- vascular diseases including complications of diabetes
- autoimmune and inflammatory conditions are myopathy, retinopathy, nephropathy, atherosclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease, transplant rejection, ischemia reperfusion injury (e.g. stroke, myocardial ischemia, intestinal reperfusion e.g.
- Cancer metastasis is a particularly treatable by the present method (see references 1-15, 47-57, 67-70, 81 and 82 for evidence of the association of Core 2 GlcNAc-T or glycans formed by Core 2 GlcNAc-T with these diseases).
- Cancers may include, for example, leukemias, lymphomas, melanomas, adenomas, sarcomas, and carcinomas of solid tissues; particularly cancers include prostate, testicular, mammary, pancreatic, cervical, uterine, kidney, lung, rectum, breast, gastric, thyroid, neck, cervix, bowel, salivary gland, bile duct, pelvis, mediastinum, urethra, bronchogenic, bladder, esophagus, colon, small intestine and sarcomas (eg. Kaposi's sarcoma) and adenomatous polyps.
- leukemias lymphomas, melanomas, adenomas, sarcomas, and carcinomas of solid tissues
- cancers include prostate, testicular, mammary, pancreatic, cervical, uterine, kidney, lung, rectum, breast, gastric, thyroid, neck, cervix, bowel, salivary gland, bil
- Particularly susceptible cancers for treatment are oral cavity carcinomas, pulmonary cancers such as pulmonary adenocarcinoma, colorectal cancer, bladder carcinoma, liver tumours, stomach tumours colon tumours, prostate cancer, testicular tumour, mammary cancer, lung tumours oral cavity carcinomas. Particular application is found in cancer or its metastasis where Core 2 GlcNAc-T activity is raised.
- pulmonary cancers such as pulmonary adenocarcinoma, colorectal cancer, bladder carcinoma, liver tumours, stomach tumours colon tumours, prostate cancer, testicular tumour, mammary cancer, lung tumours oral cavity carcinomas.
- Particular application is found in cancer or its metastasis where Core 2 GlcNAc-T activity is raised.
- the compound of the formula I is a compound of the formula II
- R 2 is H, —OH, or C 1-6 alkoxy; more preferably R 2 is H or —OH, R 4 is as defined above; and Sac 1 and Sac 3 are saccharide moieties.
- More preferred compounds are those of the formula II wherein R 4 is H, —CH 2 OH or —CH 3 ;
- R 4 is —CH 2 OH
- R 4 is —CH 2 OH and the moiety A is a glucose moiety
- Ring A is either glucose or galactose; preferably glucose; Sac 1 is selected from glucose, galactose, arabinose, xylose and rhamnose and is preferably rhamnose; Sac 3 is selected from glucose, galactose, arabinose, xylose and rhamnose; preferably glucose.
- ring A is a glucose moiety, and which formula may be written
- Rha represents rhamnose
- Glc represents glucose
- 2 and 4 are the positions of ring A to which the saccharides are attached.
- R 1 is H, —OH, C 1-6 alkoxy, —NR 5 R 6 , or Sac 1; preferably R 1 is —OH, C 1-6 alkoxy or —NR 5 R 6 ; more preferably R 1 is —NR 5 R 6
- R 3 is H, —OH or C 1-6 alkoxy; preferably R 3 is H or —OH
- R 4 and Sac 2 are as defined above;
- Preferred compounds of the formula IV are compounds in which:
- R 1 is —OH, C 1-6 alkoxy or NR 5 R 6 ;
- R 4 is H, C 1-6 alkyl or C 1-6 hydroxyalkyl; Sac 2 is glucose, galactose, arabinose, xylose and rhamnose
- More preferred compounds of the formula IV are those in which: R 1 is —NH—C 1-6 -acyl; R 4 is —CH 3 or —CH 2 OH; Most preferred are the compounds of the formula IV which are of the formula Gal ⁇ 1 ⁇ 3(6-deoxy)GalNAc ⁇ -Z
- steroid moiety denotes a moiety comprising a tetracyclic ring system shown as formula V:
- the steroid moiety ring system is modified, for example by the addition of one or more further rings and/or one or more double bonds and/or one or more substituents.
- the saccharide ring A is attached to the steroid moiety at the 3 position.
- the steroid moiety may for example have the ring system of cholestane, pregnane, androstane, estrane, cholesterol, cholane, progestin, a mineralocorticoid, such as dehydroepiandrosterone or its 7-keto or 7-hydroxy analogue or a bile acid.
- the steroid moiety is that of a steroid that is in itself beneficial or neutral.
- neutral is meant that the steroid ring is that which is considered suitable, whether as approved eg. by the FDA or as GRAS, for use in a human or animal.
- beneficial is meant that the steroid has effects of benefit to the human or animal if it were administered separately.
- the steroid moiety Z may for example be that of a steroidal sapogenin derivable from natural sources (for example plant sources) or a steroidal moiety which is itself derivable from such steroidal sapogenins by chemical modification.
- the sapogenin may for example be that of a furostanol glycoside, a spirostanol glycoside (including those with nitrogen and oxygen containing rings) a damarane glycoside or other steroidal saponin.
- the steroid moiety Z for example may be a steroid moiety of the formula VI
- Groups or rings that may be incorporated into the steroid core V or VI are selected from those set out in formulae VI a to VI e wherein the dotted lines represent the relevant rings of the steroid core.
- R 7 , R 14 , R 22 and R 24 are independently selected from H and —OH;
- R 8 , R 18 , R 23 , R 27 R 29 and R 33 are independently selected from C 1-6 alkyl; preferably R 8 , R 18 , R 23 , R 27 , R 29 and R 33 are —CH 3 ;
- R 9 , R 11 and R 16 are independently selected from H and C 1-6 alkyl; preferably R 9 , R 11 and R 16 are independently selected from H and —CH 3 ;
- R 10 is H or —OH or the H normally also present is absent and R 10 is ⁇ O;
- R 12 is H, —OH or C 1-6 acyl or a group selected from VII a or VII b; preferably R 12 is H, —OH or acetyl or a group selected from VII a or VII b;
- R 13 is H.
- R 15 is H, C 1-6 alkyl or —OH or R 13 and R 15 taken together form a —CH 2 —CH 2 — group; preferably R 15 is H, —OH or —CH 3 or R 13 and R 15 taken together form a —CH 2 —CH 2 — group;
- R 17 is H, C 1-6 alkyl or C 1-6 hydroxyalkyl; preferably R 17 is H, —CH 2 OH, or —CH 3 .
- R 19 is H or —OH.
- R 20 is H, —OH or C 1-6 alkoxy or R 19 and R 20 taken together represent the second bond of a double bond joining adjacent carbon atoms; preferably R 20 is H, —OH or —OCH 3 or R 19 and R 20 taken together represent the second bond of a double bond joining adjacent carbon atoms.
- R 21 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or a C 1-6 alkyl or C 2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, C 1-6 alkoxy and Sac 4; preferably R 21 is C 2-6 alkenyl, or a C 1-6 alkyl or C 2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, C 1-6 alkoxy and Sac 4; more preferably R 21 is C 2-6 alkenyl or a C 1-6 alkyl or C 2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, —OCH 3 and Sac 4; most preferably R 21 is selected from the group consisting of 3-methylenbutyl substituted at the 4-position by Sac4, 4-hydroxy-3-methybutanyl, 3-methyl but-2-eneyl, 2-methyl-prop-2-enyl, 3-methylbutanyl substituted
- R 25 is C 1-6 alkyl, C 1-6 hydroxyalkyl or ⁇ CH 2 ; preferably R 25 is —CH 3 , —CH 2 OH or ⁇ CH 2 ;
- R 26 is —OH
- R 28 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; preferably R 28 is C 2-6 alkenyl; most preferably it is 2-methylprop-2-enyl
- R 30 is C 1-6 hydroxyalkyl
- R 31 is C 1-6 alkyl, C 1-6 hydroxyalkyl or C 1-6 alkyl substituted by Sac 5; preferably R 31 is C 1-6 alkyl or C 1-6 alkyl substituted by Sac 5; more preferably R 31 is —CH 3 or —CH 2 -Sac 5.
- R 32 is C 1-8 alkyl, C 2-8 alkenyl or C 2-8 alkynyl; preferably R 32 is C 1-8 alkyl or C 2-8 alkenyl; more preferably 3-ethyl-4-methyl-pentanyl or 5-methyl-hex-4-enyl;
- R 34 is C 1-6 hydroxyalkyl or C 1-6 alkyl substituted by Sac 6; preferably R 34 is C 1-6 alkyl substituted by Sac 6; more preferably R 34 is —CH 2 -Sac 6;
- R 35 is C 1-6 alkyl; preferably R 35 is —CH 3 ;
- Sac 4, Sac 5 and Sac 6 are independently selected saccharides; preferably Sac 4, Sac5 and Sac 6 are independently selected monosaccharides; more preferably they are independently selected a hexose, a pentose or a tetrose; more preferably still they are independently selected from glucose, galactose, quinovose, fucose, arabinose and xylose, most preferably they are glucose.
- X is either O or NH; preferably X is O.
- Preferred steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R 9 is C 1-6 alkyl; R 11 is H; and R 12 is VII(a); preferably R 9 is C 1-6 alkyl; R 11 is H; R 12 is VII(a); R 15 is C 1-6 alkyl and R 10 is H or —OH; more preferably R 9 is C 1-6 alkyl; R 11 is H; R 12 is VII(a); R 15 is C 1-6 alkyl; R 10 is H or —OH, R 16 is C 1-6 alkyl and R 17 is C 1-6 alkyl or C 1-6 hydroxyalkyl.
- R 9 is C 1-6 alkyl; R 11 is H; and R 12 is VII(b); preferably R 9 is C 1-6 alkyl; R 11 is H; R 12 is VII(b) and R 16 , R 17 and R 15 are C 1-6 alkyl; more preferably R 9 is C 1-6 alkyl; R 11 is H; R 12 is VII(b) and R 16 , R 17 and R 15 are C 1-6 alkyl and R 10 is H or —OH.
- steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R 9 is H; R 11 is C 1-6 alkyl; and R 12 is C 1-6 acyl; preferably R 9 is H; R 11 is C 1-6 alkyl; R 12 is C 1-6 acyl; R 16 and R 17 are H R 15 is H or —OH.
- steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R 9 is H; R 11 is C 1-6 alkyl; and R 12 is VII b; preferably R 9 is H; R 11 is C 1-6 alkyl; R 12 is VIIb; R 16 and R 17 are H; and R 15 is H or —OH;
- steroid moieties Z selected from groups V which incorporate further groups VI a, VI c, VI d and VI e.
- Preferred steroid moieties Z incorporating further groups VI a are those in which R 9 is H, R 11 is C 1-6 alkyl; R 12 is H or —OH; R 16 and R 17 are H and R 21 is C 2-6 alkenyl or a C 1-6 alkyl or C 2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, —OCH 3 and Sac 4; preferably R 8 is C 1-6 alkyl and R 9 is H and R 11 is C 1-6 alkyl; R 12 is H or —OH; R 16 and R 17 are H and R 21 is 3-methylenbutyl substituted at the 4-position by Sac 4, 3-methyl but-2-eneyl, 2-methyl-prop-2-enyl, 4-hydroxy-3-methylbutanyl, 3-methylbutanyl substituted at the 4-position by Sac4, 1-hydroxy-3-methylbutanyl substituted at the 4-position by Sac4 or 1-methoxy-3-methylbutanyl substituted at the 4-position by Sac 4;
- steroid moieties Z incorporating further groups VI a are those in which R 9 is C 1-6 alkyl; R 11 is H; R 20 is H; and R 21 is a C 2-6 alkenyl; preferably R 9 is C 1-6 alkyl; R 11 is H; R 20 is H; R 21 is a C 2-6 alkenyl; and R 10 is H; more preferably R 9 is C 1-6 alkyl; R 11 is H; R 20 is H; R 21 is a C 2-6 alkenyl; R 10 is H; and R 15 is —OH or —CH 2 —CH 2 —; more preferably R 9 is C 1-6 alkyl; R 11 is H; R 20 is H; R 21 is a C 2-6 alkenyl; R 10 is H; R 15 is —OH or —CH 2 —CH 2 —; and R 16 and R 17 is C 1-6 alkyl.
- Preferred steroid moieties Z incorporating further groups VI c are those in which R 8 is C 1-6 alkyl and R 9 is H and R 11 is C 1-6 alkyl; R 12 is H or —OH; R 15 is H or —OH; R 16 and R 17 are H; more preferred steroid moieties Z incorporating further groups VI c are those in which R 8 is C 1-6 alkyl and R 9 is H and R 11 is C 1-6 alkyl; R 12 is H or —OH; R 15 is H or —OH; R 16 and R 17 are H and X is O.
- Preferred steroid moieties of formula VI a and VI b are those having the ring structures below: still more preferably having the substitutions as set forth therein.
- the chiral centre at the carbon labelled “25” can be in either the R or S configuration.
- More preferred steroid moieties, Z, of the formula VI c in which X ⁇ O are for example those having the radicals of sarsasapogenin, smilagenin, 12 ⁇ -hydroxysmilagenin, rhodeasapogenin, isorhodiasapogenin, samogenin, 12 ⁇ -hydroxysamogenin, markogenin, yonogenin, convallagenin A, convallagenin B, tokorogenin, tigogenin, neotigogenin, gitogenin, agigenin digitogenin, chlorogenin, paniculogenin, (25R)-spirostan-3 ⁇ , 17 ⁇ ,21-triol, allogenin, (25R)-5 ⁇ -spirostan-2 ⁇ ,3 ⁇ ,5 ⁇ ,6 ⁇ -tetraol, (24S,25R)-5 ⁇ -spirostan-2 ⁇ ,3 ⁇ ,5 ⁇ ,6 ⁇ ,24-pentaol, yamogenin diosgenin,
- Preferred steroid moieties, Z, of the formula VI c in which X ⁇ NH are for example those that have the radicals of: solasodine, soladulcidine, tomatidine and 5-dehydrotomatidine.
- Preferred steroidal moieties Z of the formula VI c are those having the ring structures below; still more preferably having the substitutions as set forth therein.
- steroidal moieties Z of the formula VI are those having the ring structures below; still more preferably having the substitutions as set forth therein.
- Preferred steroid moieties VI i to VI xxxii can be derived from steroidal glycoside compounds herein, of references of table 2 and additionally from references (27, 40, 76 to 78 and 86 to 93).
- Preferred compounds of the formula I combine preferred Steroid moieties —Z— with preferred saccharide moieties.
- compounds of the invention are those of the formula III in which the steroid moiety —Z— is selected from group V which incorporate the further group VIa and in which R 7 , R 9 , R 10 , R 13 , R 14 , R 16 , R 17 and R 19 are H; R 12 is H or —OH; R 8 , R 11 and R 18 are —CH 3 ; R 15 is H or —OH; R 20 is —OH or —OCH 3 and R 21 is 4-hydroxy-3-methylbutanyl, 3-methylenebutyl substituted at the 4-position by Glc, 3-methylbutanyl substituted at the 4-position by Glc, 1-hydroxy-3-methylbutanyl substituted at the 4-position by Glc or 1-methoxy-3-methylbutanyl substituted at the 4-position by Glc. It is particularly preferred that when R 21 is 3-methylenebutyl substituted at the 4-position by Glc then the compound of the formula III is compound 25 of table 1a.
- the preferred compounds have the following chemical names:
- Protodioscin is [(3 ⁇ ,22 ⁇ ,25R)-26-( ⁇ -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl O-6-deoxy- ⁇ -L-mannopyranosyl (1 ⁇ 2)-O-[6-deoxy- ⁇ -L-mannopyranosyl-(1 ⁇ 4)]- ⁇ -D-Glucopyranosidel
- pseudoprotodioscin is [(3 ⁇ ,22 ⁇ ,25R)-26-( ⁇ -D-glucopyranosyloxy)-furosta-5,20(22)-dien-3-yl O-6-deoxy- ⁇ -L-mannopyranosyl (1 ⁇ 2)-O-[6-deoxy- ⁇ -L-mannopyranosyl-(1 ⁇ 4)]- ⁇ -D-Glucopyranoside]
- protoneodioscin is [(3 ⁇ ,22 ⁇ ,25S)-26-( ⁇ -D-glucopyran
- Compound 8 is (3 ⁇ ,25R)-26-( ⁇ -D-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-6-deoxy- ⁇ -L-mannopyranosyl-(1 ⁇ 2)-O-[ ⁇ -D-glucopyranosyl-(1 ⁇ 4)]- ⁇ -D-Glucopyranoside
- compound 12 is [(3 ⁇ ,12 ⁇ ,25R)-12-hydroxyspirostan-3-yl O-6-deoxy- ⁇ -L-mannopyranosyl-(1 ⁇ 2)-[ ⁇ -D-glucopyranosyl-(1 ⁇ 4)]- ⁇ -D-glucopyranoside]
- compound 13 is [(25S)-spirost-5-ene-3 ⁇ 27-diol 3-O- ⁇ 6-deoxy- ⁇ -L-mannopyranosyl-(1 ⁇ 2)-[ ⁇ -D-glucopyranosyl-(1 ⁇ 4)]- ⁇ -D-glucopyranoside ⁇
- any preferred substituent such as C 1-6 alkyl, C 1-6 hydroxyalkyl
- substituents are more preferred with 1 to 4 carbon atoms (ie C 1-4 ), are more preferred still with 1 or 2 carbon atoms (ie methyl or ethyl) and are most preferred with only one carbon atom (ie are in the methyl form).
- partial substituents such as the C 1-6 alkyl group or C 1-6 alkoxy group of C 1-6 -alkoxy-C 1-6 -alkyl are said to be composed of from 1 to 6 carbon atoms (ie C 1-6 ) such substituents are, independently one of the other, more preferred with 1 to 4 carbon atoms (ie C 1-4 ), are more preferred still with 1 or 2 carbon atoms (ie methyl or ethyl) and are most preferred with only one carbon atom (ie are in the methyl form).
- Alkyl, alkenyl and alykynyl radicals may, where the number of carbons in the chain permits, be either straight-chain or branched chain.
- C 1-6 alkyl radicals may be, for example, methyl, ethyl, n-propyl or isopropyl, n-butyl, isobutyl or tert-butyl, isopentyl, 2,2-dimethyl propyl, n-hexyl, isohexyl and 1,3-dimethylbutyl.
- C 2-6 alkenyl radicals may be, for example, allyl, 1-methylprop-2-enyl, 2-methylprop-2-enyl, 2-methyl prop-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-but-3-enyl, 1-methyl-but-2-enyl, 3-methylbut-2-enyl; where the alkenyl radical consists of 2-8 carbon atoms, the possible arrangements include, in addition to those possible for radicals with 2-6 carbon atoms, the following preferred radicals 5-methyl-hex-5-enyl, 4-methyl-hex-5-enyl, 3,4-dimethyl-hex-2-enyl.
- C 2-6 alkynyl may be, for example, propargyl, but-2-ynyl, but-3-ynyl, 1-methylbut-3-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 4-methyl-pent-2-ynyl.
- it is propargyl, 1-methylbut-3-ynyl, pent-2-ynyl, pent-4-ynyl or 4-methyl-pent-2-ynyl.
- a C 1-6 hydroxyalkyl group may, where chemically possible, be either a C 1-6 monohydroxyalkyl or a C 1-6 dihydroxyalkyl group.
- moieties may be, in turn, substituted by a saccharide moiety it is preferred that the bond is through an oxygen to form a group such as:
- the saccharide moiety A comprises multiple chiral centres.
- each of the carbon atoms 1, 2, 3, 4 and 5 can, independently, be in the R or S form.
- A can, independently, be in either the alpha or beta anomeric form.
- the beta anomeric form is preferred.
- the saccharide moiety A can be in the D or L form; the D form is preferred.
- the monosaccharide A can take a number of forms.
- the saccharide moiety may, for example, be arranged as arabinopyranose, lyxopyranose, ribopyranose or xylopyranose; preferably it is xylopyranose or ribopyranose; more preferably it is xylopyranose.
- the saccharide moiety is a 6-deoxy hexopyranose, and may be arranged as 6-deoxyallose, 6-deoxyaltrose, 6-deoxygalactose(fucose), 6-deoxyglucose(quinovose), 6-deoxygulose, 6-deoxyidose, 6-deoxymannose(rhamnose) or 6-deoxytalose preferably it is 6-deoxyallose or quinovose; preferably it is quinovose.
- R 4 is —CH 2 OH and R 1 , R 2 and R 3 are —OH
- the saccharide moiety is a hexopyranose and may be, for example, allose, altrose, galactose, glucose gulose, idose, mannose or talose; preferably it is allose, galactose or glucose, more preferably glucose.
- R 4 is —CH 2 OH, R 2 and R 3 are —OH
- R 1 is NR 5 R 6 and R 5 and R 6 are H
- the saccharide may be arranged as a pyranosamine, for example as glucosamine, mannosamine or galactosamine.
- the saccharide may be arranged as an N-acetylpyranosamine for example N-acetylglucosamine (GlcNAc), N-acetylmannosamine or N-acetylgalactosamine (GalNAc); most preferably it is GalNAc.
- GlcNAc N-acetylglucosamine
- AlNAc N-acetylgalactosamine
- Saccharides include, but are not limited to, monosaccharides, disaccharides, tri saccharides, tetrasaccharides and polysaccharides.
- sacchari de moieties are monosaccharides, but may be independently selected as di- or oligosaccharides.
- Monosaccharides include, but are not limited to, tetroses pentoses, hexoses and heptoses; tetroses pentoses and hexoses are preferred.
- Tetroses may be for example aldotetroses, such as erithrose and threose and aldoketoses erithrulose.
- Pentoses include, but are not limited to aldopentoses, such as arabinose, lyxose, ribose and xylose and ketopentoses such as ribulose and xylulose and deoxypentoses such as 2-deoxyribose and 3-deoxyribose.
- Preferred pentoses are xylose and arabinose. Pentoses may be in the furanose (eg arabinofuranose, lyxofuranose, ribofuranose and xylofuranose) or the pyranose (eg arabinopyranose, lyxopyranose, ribopyranose and xylopyranose) forms.
- Hexoses include, but are not limited to aldohexoses, such as, allose, altrose, galactose, talose, gulose, idose, mannose and glucose (preferred are glucose, mannose, galactose, altrose, allose idose and talose) and ketokexoses such as fructose, psicose, sorbose and tagatose.
- aldohexoses such as, allose, altrose, galactose, talose, gulose, idose, mannose and glucose
- ketokexoses such as fructose, psicose, sorbose and tagatose.
- Hexoses may also be deoxy hexoses wherein an —OH group is replaced by an —H group at any position other than the bonded group.
- 6-deoxyhexoses are for example 6-deoxyallose, 6-deoxyaltrose, 6-deoxygalactose(fucose), 6-deoxyglucose(quinovose), 6-deoxygulose, 6-deoxyidose, 6-deoxymannose(rhamnose) or 6-deoxytalose.
- Deoxyhexoses may also be 2-deoxy, 3-deoxy, 4-deoxy and 5-deoxy hexoses. The oxygen may be lacking at more than one position.
- deoxyhexoses are—2-deoxy-glucose, 2-deoxygalactose, 4-deoxyfucose, 3-deoxygalactose, 2-deoxyglucose, 3-deoxyglucose, 4-deoxyglucose.
- Deoxyaldohexoses are preferred.
- Hexoses also include hexosamines such as galactosamine, glucosamine and mannosamine, n-acteyl hexosamines such as N-acetyl-galactosamine, N-acetylmannosamine and N-acetylglucosamine.
- Preferred hexoses are aldohexoses and deoxy hexoses, particularly preferred hexoses are glucose, galactose, quinovose, fucose and rhamnose.
- Hexoses may be in the furanose or pyranose form; preferably in the pyranose form.
- uronic acids for example fructuronic acid, galacturonic acid, iduronic acid, glucuronic acid, guluronic acid, mannuronic acid and tagaturonic acid; sedoheptulose, sialic acid, neuraminic acid, muramic acid, N-acetylneuraminic acid, N-acetylmuramic acid, O-acetylneuraminic acid, and N-glycolylneuraminic acid.
- uronic acids for example fructuronic acid, galacturonic acid, iduronic acid, glucuronic acid, guluronic acid, mannuronic acid and tagaturonic acid
- sedoheptulose sialic acid, neuraminic acid, muramic acid, N-acetylneuraminic acid, N-acetylmuramic acid, O-acetylneuraminic acid, and N-glycolylneuraminic acid.
- aldohexoses and deoxyhexoses are preferred; of pentoses, aldopentoses and deoxy-pentoses (particularly deoxyaldopentoses) are preferred.
- esters of compounds of the formula 1 are for example, an ester with an aliphatic or aromatic carboxylic or sulphonic acid.
- Aliphatic carboxylic acids may be for example of up to 6 carbon atoms, for example a methyl, ethyl, tert-butyl succinyl or malyl.
- Aromatic carboxylic acids may for example benzoic acid, sulphonic acids may be methylsulphonic or p-toluenesulphonic acid, and include esters at any available esterifiable position.
- esters further include known compounds in which the sugar —OH groups are esterified with an aliphatic carboxylic acid of up to 6 carbon atoms. Also included are known esters at the carbon 26-position with compounds such as hydroxymethylgluteryric acid or its methyl ester (for example compound 19 and structure VI xxiv).
- ethers are, for example, with C 1-6 hydroxyalkyl compounds which may be formed at any of the available —OH groups, for example on the saccharide moieties, or steroid moieties by converting one or more of the —OH groups to alkoxy groups (e.g. 61, 84, 85 incorporated herein by reference).
- a suitable pharmaceutically-acceptable salt form of the compounds of the formula I is, for example, an acid addition salt with an inorganic or organic acid, for example hydrochloric, hydrobromic, trifluoroacetic or maleic acid; or an alkali metal, for example sodium, an alkaline earth metal, for example calcium, or ammonium, for example tetra(2-hydroxyethyl)ammonium, salt.
- an inorganic or organic acid for example hydrochloric, hydrobromic, trifluoroacetic or maleic acid
- an alkali metal for example sodium, an alkaline earth metal, for example calcium, or ammonium, for example tetra(2-hydroxyethyl)ammonium, salt.
- Many compounds of the invention are hydroxylated steroids. It is known in the art that such compounds, when exposed to solvent such as alcohols during purification or preparation, may be converted to alkoxy derivatives or to other derivatives such as methylketals (which revert to the original compounds upon drying).
- Particularly furostanol compounds of the formula VIa in which the carbon at the at the 22-position of the furostanol structure, is substituted by —OH, may be converted to alkoxy derivatives when exposed to alcohols.
- such compounds may become methoxy derivatives when purified from plant sources using methanol-containing solvents. Alternatively they may be converted to the corresponding alkoxy by reflux in an appropriate anhydrous alcohol at elevated temperature, for example methanol (36).
- Such alkoxylated compounds are also compounds of the invention.
- the compounds of the invention are purified from natural sources it is preferred that they are used in isolated form.
- isolated is meant that the compound is at least 1% pure, conveniently it is at least 10% pure, more conveniently at least 30% pure, preferably it is at least 50% pure more preferably it is at least 80% pure still more preferably it is at least 90% pure and most preferably it is at least 95% pure.
- the purity of the compound is conveniently expressed as a ratio of UV absorption associated with the compound to UV absorption associated with other material in the sample, conveniently at 205 nm.
- the purity of the compound may be measured for example using a chromatography system such as for example TLC or HPLC such as are described in the references herein, particularly in those references relating to the compound in question, or in applicants co pending application WO05/060977
- compounds of the invention may be synthesised via a number of routes known to the skilled worker. For example by glycosylation of appropriate aglycones.
- an suitable aglycone may be prepared, either by isolation from a natural source (27 and references therein), by deglycosylation of a suitable glycosylated compound (for example those compounds disclosed in (27) or herein), or by chemical synthesis from a variety of starting material that are readily available.
- spirostanol aglycones wherein X ⁇ O or X ⁇ NH may be, for example, sarsapogenin, smilagenin, 12 ⁇ -hydroxysmilagenin, Rhodeasapogenin, Isorhodiasapogenin, Samogenin, 12 ⁇ -hydroxysamogenin, Markogenin, Yonogenin, Convallagenin A, Convallagenin B, Tokorogenin, Tigogenin, Neotigogenin, Gitogenin, Agigenin Digitogenin, Chlorogenin, Paniculogenin, (25R)-Spirostan-3 ⁇ , 17 ⁇ 21-triol, Allogenin, (25R)-5 ⁇ -Spirostan-2 ⁇ ,3 ⁇ 3,5 ⁇ ,6 ⁇ -tetraol, (24S,25R)-5 ⁇ -Spirostan-2 ⁇ ,
- Deglycosylation of, for example steroidal glycosides may be simply carried out by acid hydrolysis, for example in a 50:50 mix of 2N HCl: dioxane at 100° C. in a sealed tube for 4.5 hrs (36—incorporated herein by reference).
- furostanol and spirostanol saponins can be inter converted using a ⁇ -glucosidase and pseudosaponins maybe cyclised to form the spirostanol derivative (63, 65—incorporated herein by reference).
- aglycone refers to steroidal glycosides wherein the saccharide moieties are not present (e.g. page 29 line 18).
- the compounds may have other substituents at the position originally occupied by the saccharide moiety.
- Particularly aglycones that are furostanol saponins when not glycosylated may be in the ring closed state as the equivalent spirostanol compounds.
- Steroidal glycosides are compounds having a steroid or substituted steroid core, to which is attached one or more saccharide moieties.
- a steroidal sapogenin is the aglycone of a steroidal saponin.
- a steroidal saponin is a naturally derived steroidal glycoside.
- An anti cell adhesion agent is an agent that reduces the adhesion of cells to a substrate such as platelets or the lining of blood vessels or other tissues
- an anti cell-cell interaction agent is an agent that reduces the interaction between cells.
- An anti cellular extravasation agent is an agent that reduces the passage of cells from the blood stream through the walls of blood vessels.
- treating includes treating as prophylaxis or treatment of a current or remitting illness.
- C 1-6 acyl is —CO—C 1-5 -alkyl.
- a compound of formula I as an anti cell adhesion agent, an anti cell-cell interaction agent or an anti cellular extravasation agent.
- a pharmaceutical composition comprising compound of the formula I.
- Medicaments of the invention comprising compounds of the formula I will typically be prepared in a sterile and pyrogen free form. They can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- oral or parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- the medicament may be made up in liquid form in which case it will typically, in addition to the compound of the formula I, comprise a pharmaceutically acceptable diluent or it may be made up in solid form.
- the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
- Tablets for oral use may include the active ingredients mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
- suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are examples of suitable disintegrating agents.
- Binding agents include, for example starch and gelatine, while the lubricating agent, if present, may for example, be magnesium stearate, stearic acid or talc.
- the tablets may be coated with an enteric coating material, such as glyceryl mono stearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
- enteric coating material such as glyceryl mono stearate or glyceryl distearate
- Capsules for oral use include hard gelatine capsules in which the active ingredient is mixed with a solid diluent, and soft gelatine capsules wherein the active ingredients is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil
- Formulations for rectal administration may for example be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may for example be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- the compounds of the invention will typically be provided in a pharmaceutically acceptable diluent to provide sterile solutions, emulsions, liposome formulations or suspensions.
- a pharmaceutically acceptable diluent to provide sterile solutions, emulsions, liposome formulations or suspensions.
- the preparation will be buffered to an appropriate pH and isotonicity.
- suitable diluents include Ringer's solution and isotonic sodium chloride.
- Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin.
- Suitable preservatives include ethyl and n-propyl p-hydroxybenzoate.
- the isolated Core 2 GlcNAc-T inhibitors of the invention may also be incorporated into a food or beverage product.
- a suitable dose of Core 2 GlcNAc-T inhibitor will be in the range of 100 ng to 10 mg per kilogram body weight of the recipient per day, preferably in the range of 1 ⁇ g to 5.0 mg/kg/d.
- the desired dose is presented once daily or several times a day in sub doses.
- These sub-doses may be administered in unit dosage forms, for example, containing 1 ⁇ g to 1500 mg, preferably 40 ⁇ g to 1000 mg, and most preferably 50 ⁇ g to 700 mg of active ingredient per unit dosage form.
- Glc is glucose and Rha is rhamnose.
- the annotation 2,3 and 2,4 denote the position of attachment of the saccharides to the central monosaccharide.
- Example Compound references Compound name 1 36 Protodioscin 2 37 Pseudoprotodioscin 3 36 Protoneodioscin 4 36 Methylprotodioscin 5 36 Methylprotoneodioscin 6 17 Trigoneoside IVa 7 22, 17 Glycoside F, protodeltonin, deltoside, 8 42 No name 9 19 Pardarinoside C 10 19 Pardarinoside D 11 39 Dioscin 12 38 Not named 13 20, 40, 41, 42 Not named 14 40, 42 Not named 15 40, 41, 20, 21 Not named 16 41, 20 Not named 17 42 Not named 18 43 Not named 19 26, 42, 25 Balanitin VI 20 24, 71 Deltonin 21 18, 23 Shatavarin I 22 18, 23 Shatavarin IV 23 20 Not named 24 21 Not named 25 WOO5060977 Not named 26 20 Not named 27 36 Protogracillin*** ***comparative example compound.
- the human leukocytic cell-line (U937) was cultured in RPMI supplemented with 10% foetal calf serum, 2 mM glutamine, 100 IU/ml penicillin and 100 ⁇ g/ml streptomycin.
- Glucose induction of Core 2 GlcNAc-T leukocytes (U937 cells) were exposed to normal glucose (5.8 mM) or high glucose (15 mM) for 24 hours at 37° C. After incubation, the cells maybe lysed and frozen at ⁇ 20° C. until used for the measurement of core 2 GlcNAc-T or used immediately.
- TNF- ⁇ induction of core 2 GlcNAc-T Human leukocytes(U937 cells) were exposed to human recombinant TNF-alpha (8 pg/ml) in the presence and absence of test compounds After 24 h incubation, the activity of core 2 GlcNAc-T was measured, and expressed as pmoles/h/mg protein
- core 2 GlcNAc-T activity leukocytes were washed in PES, frozen and lysed in 0.9% Triton X-100 at 0° C. The activity of core 2 GlcNAc-T was measured as described below. Cell free assays are preformed by substituting heart lysates for cell lysates.
- the reaction was performed in a reaction mixture containing 50 mM 2(N-morpholino)ethanesulfonic acid (MES, Sigma, Dorset, UK), pH 7.0, 1 mM UDP-6 ['H]-N-acetylglucosamine (16,000 dpm/nmol, NEN Life Science Products, Hounslow, UK), 0.1 M GlcNAc (Sigma, Dorset, Okla.), 1 mM Gal ⁇ 1-3GalNAc ⁇ -p-nitrophenol (Sigma, Dorset, UK) as substrate, and 16 ⁇ l of lysate (100-200 ⁇ g protein) for a final volume of 32 ⁇ l.
- MES 2(N-morpholino)ethanesulfonic acid
- pH 7.0 pH 7.0
- 1 mM UDP-6 ['H]-N-acetylglucosamine (16,000 dpm/nmol, NEN Life Science Products, Hounslow, UK
- GlcNAc Sigma, Dorset, Okla
- Compound C (at 20 ng/ml) was found to inhibit Core 2 GlcNAc-T approximately 98.5% compared to controls, in TNF- ⁇ treated Human leukocytes (U937 cells).
- the sample of compound C was approximately 82.5% pure by HPLC at 205 nM
- Trigoneoside IVa The approximate IC 50 of Trigoneoside IVa was found to be between 0.25 nM and 0.9 nM in cell free systems. Further analysis of a sample prepared according to applicants co pending WO05/060977 indicates that it contains approximately 7.5% protodioscin and 9% Trigonelloside C (17).
- the IC 50 of Glycoside F was found to be approximately 5 nM. Further analysis of the preparation indicates that it contains a small amount of Trigonelloside C.
- the IC 50 of Protodioscin (93.3% pure) produced as described in applicants co pending WO05/060977 was found to be approximately 20 nM.
- the sample contained 1.5% Trigoneoside IVa.
- Trigoneoside IVa activity could account for at least some of the activity seen in the protodioscin sample prepared as per WO05/060977.
- Trigonelloside C is similar to Protodioscin but is the opposite isomer at carbon 25.
- a preparation of this compound according to co pending WO05/060977 was 98.2% pure and contained no measurable quantity of other Core 2 GlcNAc-T inhibitors.
- a preparation of Trigonelloside C prepared according to WO05/060977 inhibited Core 2 GlcNAc-T 69% at 2.5 nM.
Abstract
A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereof
wherein
R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1;
R2 is H, —OH, C1-6 alkoxy or Sac 2;
R3 is H, —OH, C1-6 alkoxy or Sac 3;
R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl;
R5 is H, C1-6 alkyl or C1-6 acyl;
R6 is H, C1-6 alkyl or C1-6 acyl;
Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and
Z is a steroid moiety;
or a pharmaceutically acceptable salt, ether or ester form thereof
Description
- The present invention relates to the use of known and novel compounds as pharmaceutical actives against diseases susceptible to treatment by modulation, eg. inhibition, of the enzyme Core 2 GlcNAc-transferase (EC 2.4.1.162), also known as UDP-GlcNAc:Galβ1,3GalNAc-R (GlcNAc to GalNAc) β-1,6-N-acetylglucosaminyl transferase (core 2β-1,6 N-acetylaminotransferase, hereinafter referred to as Core 2 GlcNAc-T.
- Inhibitors of Core 2 GlcNAc-T, and the present compounds in particular, have application in therapy for diseases in which core 2 GlcNAc-T is implicated and especially those in which the enzyme activity is raised relative to the normal level in the tissue type concerned, or those conditions in which it is advantageous to lower the activity of core 2 GlcNAc-T for example to its normal level or below. Examples of such conditions are inflammatory diseases such as atherosclerosis and multiple sclerosis, diabetes, cancer and its metastasis.
- Inhibitors of Core 2 GlcNAc-T are known but none are in clinical development as isolated actives for pharmaceutical use. Examples of known compounds are disclosed in WO0187548, Kuhns (15), Hindsgaul (45) and Toki (46).
- Applicant's co-pending application WOO5060977 (incorporated herein by reference) discloses known and novel steroidal glycosides that have therapeutic use as Core GlcNAc-T inhibitors, discusses the basis for use of such inhibitors in therapy and discloses published documents detailing the basis for Core 2 GlcNAc-T involvement in a number of diseases. The present application discloses further steroidal glycoside compounds that are suitable for use in therapy for diseases in which Core 2 GlcNAc-T is implicated and additional such conditions in which such compounds have a therapeutic use.
- Some of the presently disclosed steroidal glycosides have been tested previously in a limited number of disease paradigms. For example in protection against gastric mucosal lesions in rats (80), in mouse ear edema tests for anti inflammatory activity (79), in treatment of dementia (U.S. Pat. No. 6,593,301) as “immuno-modulators” and spermatogenesis and ovulation stimulators (74) and as adjuvants (75). Compounds of the invention have also been used in cytotoxicity assays (e.g. 36, 40, 72), however cytotoxic concentrations are several orders of magnitude higher than those currently disclosed for inhibition of Core 2 GlcNAc-T activity. None of the aforementioned publications discloses that certain steroidal glycosides are inhibitors of Core 2 GlcNAc-T.
- Certain plant sterol compounds, some of which are used as dietary supplements, impede the uptake of cholesterol from the gut and consequently lower plasma LDL cholesterol. However these compounds are generally used in doses of several grams per day and are not known to be inhibitors of Core 2 GlcNAc-T.
- In a first aspect the present invention is provided a method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T, particularly raised activity, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of formula I to a patient in need thereof
- wherein
- R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1;
- R2 is H, —OH, C1-6 alkoxy or Sac 2;
- R3 is H, —OH, C1-6 alkoxy or Sac 3;
- R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl;
- R5 is H, C1-6 alkyl or C1-6 acyl;
- R6 is H, C1-6 alkyl or C1-6 acyl;
- Sac 1, Sac 2 and Sac 3 are independently selected saccharide moieties attached to the ring through an oxygen; and
- Z is a steroid moiety;
- or a pharmaceutically acceptable salt, ether, ester or tautomeric form thereof.
- When one of R1 to R3 is a saccharide moiety, the ring of formula I is designated ring A.
- R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1; preferably R1 is H, —OH, or Sac 1; more preferably R1 is Sac 1;
- R2 is H, —OH, C1-6 alkoxy or Sac 2; preferably R2 is H, —OH or Sac 2; more preferably R2is —OH;
- R3 is H, —OH, C1-6 alkoxy or Sac 3; preferably R3 is H, —OH or Sac 3; more preferably R3 is Sac 3;
- R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; preferably R4 is H, C1-6 alkyl or C1-6 hydroxyalkyl; more preferably R4 is H, —CH2OH or —CH3; more preferably still R4 is —CH2OH; more preferably still R4 is —CH2OH and the resultant moiety is a glucose or galactose moiety; most preferably R4 is —CH2OH and the resultant moiety is a glucose moiety;
- R5 is H, C1-6 alkyl or C1-6 -acyl; preferably R5 is H or C1-6 alkyl; more preferably R5 is H or —CH3; most preferably R5is H;
- R6 is H, C1-6 alkyl or C1-6 acyl; preferably R6 is H—CH3 or —COCH3; most preferably R6 is —COCH3; and
- Sac 1, Sac 2 and Sac 3 are saccharide moieties attached to the ring through an oxygen; preferably Sac 1 Sac 2 and Sac 3 are independently selected from monosaccharide moieties and disaccharide moieties; preferably they are monosaccharide moieties; more preferably Sac 1 Sac 2 and Sac 3 are independently selected from a tetrose a pentose and a hexose. Preferably Sac 1 is selected from a pentose, a deoxy-aldohexose and an aldohexose; more preferably Sac 1 is selected from arabinose, xylose, glucose, mannose, galactose, and a deoxy-aldohexose; more preferably Sac 1 is selected from arabinose, xylose, glucose, mannose, galactose, and a 6-deoxyaldohexose; more preferably Sac 1 is selected from glucose, galactose, arabinose, xylose and rhamnose; most preferably it is rhamnose;
- Preferably Sac 2 is selected from a pentose, a deoxy-aldohexose and an aldohexose; more preferably Sac 2 is selected from arabinose, xylose, glucose, mannose, galactose, and a deoxyaldohexose; more preferably Sac 2 is selected from arabinose, xylose, glucose, mannose, galactose, and a 6-deoxyaldohexose; more preferably Sac 2 is selected from. glucose, galactose, arabinose, xylose and rhamnose;
- Preferably Sac 3 is selected from a pentose, a deoxy aldohexose and an aldohexose; arabinose, xylose, quinovose rhamnose or an aldohexose, more preferably Sac 3 is selected from arabinose, xylose, quinovose, rhamnose, mannose, glucose and galactose, most preferably Sac 3 is rhamnose or glucose;
- Z is a steroid moiety;
- or a pharmaceutically acceptable salt, ether, ester or tautomeric form thereof.
- The present inventors have determined that because of its involvement in the synthesis of particular branched oligosaccharides, Core 2 GlcNAc-T modulation, particularly inhibition, may be used to treat inter alia, vascular diseases, (including complications of diabetes), autoimmune and inflammatory conditions. Particular conditions subject to treatment by the present invention are myopathy, retinopathy, nephropathy, atherosclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease, transplant rejection, ischemia reperfusion injury (e.g. stroke, myocardial ischemia, intestinal reperfusion e.g. after hemorrhagic shock,), restenosis, ileitis, Crohn's disease, thrombosis, cholitis including for example ulcerative cholitis), lupus, frost bite injury, acute leukocyte mediated lung injury (eg adult respiratory distress syndrome), traumatic shock, septic shock, nephritis, psoriasis, cholicytitis, cirrhosis, diverticulitis, fulminant hepatitis, gastritis, gastric and duodenal ulcers, hepatorenal syndrome, irritable bowel syndrome, jaundice, pancreatitis, ulcerative cholitis, human granulocyte ehlichiosis, Wiskott-Aldrich syndrome T-cell activation, AIDS, infection with viruses, bacteria, protozoa and parasites adapted to use particular core 2 derived glycans and cancer. Cancer metastasis is a particularly treatable by the present method (see references 1-15, 47-57, 67-70, 81 and 82 for evidence of the association of Core 2 GlcNAc-T or glycans formed by Core 2 GlcNAc-T with these diseases).
- Cancers may include, for example, leukemias, lymphomas, melanomas, adenomas, sarcomas, and carcinomas of solid tissues; particularly cancers include prostate, testicular, mammary, pancreatic, cervical, uterine, kidney, lung, rectum, breast, gastric, thyroid, neck, cervix, bowel, salivary gland, bile duct, pelvis, mediastinum, urethra, bronchogenic, bladder, esophagus, colon, small intestine and sarcomas (eg. Kaposi's sarcoma) and adenomatous polyps. Particularly susceptible cancers for treatment are oral cavity carcinomas, pulmonary cancers such as pulmonary adenocarcinoma, colorectal cancer, bladder carcinoma, liver tumours, stomach tumours colon tumours, prostate cancer, testicular tumour, mammary cancer, lung tumours oral cavity carcinomas. Particular application is found in cancer or its metastasis where Core 2 GlcNAc-T activity is raised.
- Preferably the compound of the formula I is a compound of the formula II
- wherein
- R2 is H, —OH, or C1-6 alkoxy; more preferably R2 is H or —OH, R4 is as defined above; and Sac 1 and Sac 3 are saccharide moieties.
- More preferred compounds are those of the formula II wherein R4 is H, —CH2OH or —CH3;
- Particularly preferred still are those compounds wherein: R4 is —CH2OH;
- More preferred still are those compounds wherein: R4 is —CH2OH and the moiety A is a glucose moiety;
- In a preferred combination Ring A is either glucose or galactose; preferably glucose; Sac 1 is selected from glucose, galactose, arabinose, xylose and rhamnose and is preferably rhamnose; Sac 3 is selected from glucose, galactose, arabinose, xylose and rhamnose; preferably glucose.
- Most preferred are compounds of the formula I which are of the formula III:
- Wherein the ring A is a glucose moiety, and which formula may be written
- In which Rha represents rhamnose, Glc represents glucose and 2 and 4 are the positions of ring A to which the saccharides are attached.
- Most preferred are compounds which are 6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranosides of steroid moieties Z.
- Alternatively compounds of the formula I are compounds of the formula IV:
- wherein:
- wherein R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1; preferably R1 is —OH, C1-6 alkoxy or —NR5R6; more preferably R1 is —NR5R6
- R3 is H, —OH or C1-6 alkoxy; preferably R3 is H or —OH
- R4 and Sac 2 are as defined above;
- Preferred compounds of the formula IV are compounds in which:
- R1 is —OH, C1-6 alkoxy or NR5R6; R4 is H, C1-6 alkyl or C1-6 hydroxyalkyl; Sac 2 is glucose, galactose, arabinose, xylose and rhamnose
- More preferred compounds of the formula IV are those in which: R1 is —NH—C1-6-acyl; R4 is —CH3 or —CH2OH; Most preferred are the compounds of the formula IV which are of the formula Galβ1→3(6-deoxy)GalNAcα-Z
- The term “steroid moiety” denotes a moiety comprising a tetracyclic ring system shown as formula V:
- Typically the steroid moiety ring system is modified, for example by the addition of one or more further rings and/or one or more double bonds and/or one or more substituents. Typically the saccharide ring A is attached to the steroid moiety at the 3 position. The steroid moiety may for example have the ring system of cholestane, pregnane, androstane, estrane, cholesterol, cholane, progestin, a mineralocorticoid, such as dehydroepiandrosterone or its 7-keto or 7-hydroxy analogue or a bile acid.
- In one preferred embodiment the steroid moiety is that of a steroid that is in itself beneficial or neutral. By neutral is meant that the steroid ring is that which is considered suitable, whether as approved eg. by the FDA or as GRAS, for use in a human or animal. By beneficial is meant that the steroid has effects of benefit to the human or animal if it were administered separately.
- The steroid moiety Z may for example be that of a steroidal sapogenin derivable from natural sources (for example plant sources) or a steroidal moiety which is itself derivable from such steroidal sapogenins by chemical modification. The sapogenin may for example be that of a furostanol glycoside, a spirostanol glycoside (including those with nitrogen and oxygen containing rings) a damarane glycoside or other steroidal saponin. The steroid moiety Z for example may be a steroid moiety of the formula VI
- Groups or rings that may be incorporated into the steroid core V or VI are selected from those set out in formulae VI a to VI e wherein the dotted lines represent the relevant rings of the steroid core.
- wherein:
- R7, R14, R22 and R24 are independently selected from H and —OH;
- R8, R18, R23, R27 R29 and R33 are independently selected from C1-6 alkyl; preferably R8, R18, R23, R27, R29 and R33 are —CH3;
- R9, R11 and R16 are independently selected from H and C1-6 alkyl; preferably R9, R11 and R16 are independently selected from H and —CH3;
- R10 is H or —OH or the H normally also present is absent and R10 is ═O;
- R12 is H, —OH or C1-6 acyl or a group selected from VII a or VII b; preferably R12 is H, —OH or acetyl or a group selected from VII a or VII b;
- R13 is H.
- R15 is H, C1-6 alkyl or —OH or R13 and R15 taken together form a —CH2—CH2— group; preferably R15 is H, —OH or —CH3 or R13 and R15 taken together form a —CH2—CH2— group;
- R17 is H, C1-6 alkyl or C1-6 hydroxyalkyl; preferably R17 is H, —CH2OH, or —CH3.
- R19 is H or —OH.
- R20 is H, —OH or C1-6 alkoxy or R19 and R20 taken together represent the second bond of a double bond joining adjacent carbon atoms; preferably R20 is H, —OH or —OCH3 or R19 and R20 taken together represent the second bond of a double bond joining adjacent carbon atoms.
- R21 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or a C1-6 alkyl or C2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, C1-6 alkoxy and Sac 4; preferably R21 is C2-6 alkenyl, or a C1-6 alkyl or C2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, C1-6 alkoxy and Sac 4; more preferably R21 is C2-6 alkenyl or a C1-6 alkyl or C2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, —OCH3 and Sac 4; most preferably R21 is selected from the group consisting of 3-methylenbutyl substituted at the 4-position by Sac4, 4-hydroxy-3-methybutanyl, 3-methyl but-2-eneyl, 2-methyl-prop-2-enyl, 3-methylbutanyl substituted at the 4-position by Sac4, 1-hydroxy-3-methylbutanyl substituted at the 4-position by Sac4 or 1-methoxy-3-methylbutanyl substituted at the 4-position by Sac4,
- R25 is C1-6 alkyl, C1-6 hydroxyalkyl or ═CH2; preferably R25 is —CH3, —CH2OH or ═CH2;
- R26 is —OH;
- R28 is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; preferably R28 is C2-6 alkenyl; most preferably it is 2-methylprop-2-enyl
- R30 is C1-6 hydroxyalkyl;
- R31 is C1-6 alkyl, C1-6 hydroxyalkyl or C1-6 alkyl substituted by Sac 5; preferably R31 is C1-6 alkyl or C1-6 alkyl substituted by Sac 5; more preferably R31 is —CH3 or —CH2-Sac 5.
- R32 is C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl; preferably R32 is C1-8 alkyl or C2-8 alkenyl; more preferably 3-ethyl-4-methyl-pentanyl or 5-methyl-hex-4-enyl;
- R34 is C1-6 hydroxyalkyl or C1-6 alkyl substituted by Sac 6; preferably R34 is C1-6 alkyl substituted by Sac 6; more preferably R34 is —CH2-Sac 6;
- R35 is C1-6 alkyl; preferably R35 is —CH3; and
- Sac 4, Sac 5 and Sac 6 are independently selected saccharides; preferably Sac 4, Sac5 and Sac 6 are independently selected monosaccharides; more preferably they are independently selected a hexose, a pentose or a tetrose; more preferably still they are independently selected from glucose, galactose, quinovose, fucose, arabinose and xylose, most preferably they are glucose.
-
- X is either O or NH; preferably X is O.
- Preferred steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R9 is C1-6 alkyl; R11 is H; and R12 is VII(a); preferably R9 is C1-6 alkyl; R11 is H; R12 is VII(a); R15 is C1-6 alkyl and R10 is H or —OH; more preferably R9 is C1-6 alkyl; R11 is H; R12 is VII(a); R15 is C1-6 alkyl; R10 is H or —OH, R16 is C1-6 alkyl and R17 is C1-6 alkyl or C1-6 hydroxyalkyl.
- Further preferred steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R9 is C1-6 alkyl; R11 is H; and R12 is VII(b); preferably R9 is C1-6 alkyl; R11 is H; R12 is VII(b) and R16, R17 and R15 are C1-6 alkyl; more preferably R9 is C1-6 alkyl; R11 is H; R12 is VII(b) and R16, R17 and R15 are C1-6 alkyl and R10 is H or —OH.
- Further preferred steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R9 is H; R11 is C1-6 alkyl; and R12 is C1-6 acyl; preferably R9 is H; R11 is C1-6 alkyl; R12 is C1-6 acyl; R16 and R17 are H R15 is H or —OH.
- Further preferred steroid moieties Z that do not incorporate further groups VI(a) to VI(e) are those in which R9 is H; R11 is C1-6 alkyl; and R12 is VII b; preferably R9 is H; R11 is C1-6 alkyl; R12 is VIIb; R16 and R17 are H; and R15 is H or —OH;
- More preferred are steroid moieties Z selected from groups V which incorporate further groups VI a, VI c, VI d and VI e.
- Preferred steroid moieties Z incorporating further groups VI a are those in which R9 is H, R11 is C1-6 alkyl; R12 is H or —OH; R16 and R17 are H and R21 is C2-6 alkenyl or a C1-6 alkyl or C2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, —OCH3 and Sac 4; preferably R8 is C1-6 alkyl and R9 is H and R11 is C1-6 alkyl; R12 is H or —OH; R16 and R17 are H and R21 is 3-methylenbutyl substituted at the 4-position by Sac 4, 3-methyl but-2-eneyl, 2-methyl-prop-2-enyl, 4-hydroxy-3-methylbutanyl, 3-methylbutanyl substituted at the 4-position by Sac4, 1-hydroxy-3-methylbutanyl substituted at the 4-position by Sac4 or 1-methoxy-3-methylbutanyl substituted at the 4-position by Sac 4;
- Alternatively, steroid moieties Z incorporating further groups VI a are those in which R9 is C1-6 alkyl; R11 is H; R20 is H; and R21 is a C2-6 alkenyl; preferably R9 is C1-6 alkyl; R11 is H; R20 is H; R21 is a C2-6 alkenyl; and R10 is H; more preferably R9 is C1-6 alkyl; R11 is H; R20 is H; R21 is a C2-6 alkenyl; R10 is H; and R15 is —OH or —CH2—CH2—; more preferably R9 is C1-6 alkyl; R11 is H; R20 is H; R21 is a C2-6 alkenyl; R10 is H; R15 is —OH or —CH2—CH2—; and R16 and R17 is C1-6 alkyl.
- Preferred steroid moieties Z incorporating further groups VI c are those in which R8 is C1-6 alkyl and R9 is H and R11 is C1-6 alkyl; R12 is H or —OH; R15 is H or —OH; R16 and R17 are H; more preferred steroid moieties Z incorporating further groups VI c are those in which R8 is C1-6 alkyl and R9 is H and R11 is C1-6 alkyl; R12 is H or —OH; R15 is H or —OH; R16 and R17 are H and X is O.
- Preferred steroid moieties of formula VI a and VI b are those having the ring structures below: still more preferably having the substitutions as set forth therein.
- In each case the chiral centre at the carbon labelled “25” can be in either the R or S configuration.
- More preferred steroid moieties, Z, of the formula VI c in which X═O are for example those having the radicals of sarsasapogenin, smilagenin, 12β-hydroxysmilagenin, rhodeasapogenin, isorhodiasapogenin, samogenin, 12β-hydroxysamogenin, markogenin, yonogenin, convallagenin A, convallagenin B, tokorogenin, tigogenin, neotigogenin, gitogenin, agigenin digitogenin, chlorogenin, paniculogenin, (25R)-spirostan-3β, 17α,21-triol, allogenin, (25R)-5α-spirostan-2α,3β,5α,6α-tetraol, (24S,25R)-5α-spirostan-2α,3β,5α,6β,24-pentaol, yamogenin diosgenin, yuccagenin, lilagenin, ruscogenin, (25S)-ruscogenin, neopraserigenin, pennogenin, isonuatigenin, cepagenin, 24a-hydroxypennogenin, ophiogenin, sibiricogenin, convallamarogenin, neoruscogenin, hecogenin, neohecogenin, manogenin, sisalagenin and hispigenin.
- Preferred steroid moieties, Z, of the formula VI c in which X═NH are for example those that have the radicals of: solasodine, soladulcidine, tomatidine and 5-dehydrotomatidine.
- Preferred steroidal moieties Z of the formula VI c are those having the ring structures below; still more preferably having the substitutions as set forth therein.
- Further preferred steroidal moieties Z of the formula VI are those having the ring structures below; still more preferably having the substitutions as set forth therein.
- Preferred steroid moieties VI i to VI xxxii can be derived from steroidal glycoside compounds herein, of references of table 2 and additionally from references (27, 40, 76 to 78 and 86 to 93).
- Preferred compounds of the formula I combine preferred Steroid moieties —Z— with preferred saccharide moieties.
- In one embodiment compounds of the invention are those of the formula III in which the steroid moiety —Z— is selected from group V which incorporate the further group VIa and in which R7, R9, R10, R13, R14, R16, R17 and R19 are H; R12 is H or —OH; R8 , R11 and R18 are —CH3; R15 is H or —OH; R20 is —OH or —OCH3 and R21 is 4-hydroxy-3-methylbutanyl, 3-methylenebutyl substituted at the 4-position by Glc, 3-methylbutanyl substituted at the 4-position by Glc, 1-hydroxy-3-methylbutanyl substituted at the 4-position by Glc or 1-methoxy-3-methylbutanyl substituted at the 4-position by Glc. It is particularly preferred that when R21 is 3-methylenebutyl substituted at the 4-position by Glc then the compound of the formula III is compound 25 of table 1a.
- Particularly preferred compounds of the formula I are:
- Protodioscin, pseudoprotodioscin, protoneodioscin, methylprotodioscin, methylprotoneodioscin, Trigoneoside IVa, glycoside F, Pardarinoside C, Pardarinoside D, dioscin, Balanitin VI, Deltonin, Shatavarin I and Shatavarin IV.
- Further preferred compounds that are so far un named are Compounds 8, 12, 13, 14, 15, 16, 17, 18, 23, 24, 25 and 26 of table 2.
- The preferred compounds have the following chemical names:
- Protodioscin is [(3β,22α,25R)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl (1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-Glucopyranosidel, pseudoprotodioscin is [(3β,22α,25R)-26-(β-D-glucopyranosyloxy)-furosta-5,20(22)-dien-3-yl O-6-deoxy-α-L-mannopyranosyl (1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-Glucopyranoside], protoneodioscin is [(3β,22α,25S)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl (1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-Glucopyranoside], methylprotodioscin is [(3β,22α,25R)-26-(β-D-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl (1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-Gluco-pyranoside], methylprotoneodioscin is [(3β,22α,25S)-26-(β-D-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl (1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-Glucopyranoside], Trigoneoside IVa is (3β,25S)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, glycoside F is (3β,25R)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, Pardarinoside C is (3β,5α,22α,25R)-26-(acetyloxy)-14,17-dihydroxy-22-methoxyfurostan-3-yl O-6-deoxy-α-L-annopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-Glucopyranoside, Pardarinoside D is β-D-glucopyranoside, (3β,5α,22α,25R)-26-(acetyloxy)-17-hydroxy-22-methoxyfurostan-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, dioscin is [(3β,25R)-spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-glucopyranoside], Balanitin VI is (3β,25S)-spirost-5-en-3-yl-O-α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-β-D-glucopyranoside, Deltonin is (3β,25R)-spirost-5-en-3-yl-O-α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-β-D-glucopyranoside, Shatavarin I is (3β,5β,22α,25S)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurostan-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, Shatavarin IV is (3β,5β,25S)-spirostan-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-β-D-glucopyranoside,
- Compound 8 is (3β,25R)-26-(β-D-glucopyranosyloxy)-22-methoxyfurost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-Glucopyranoside, compound 12 is [(3β,12α,25R)-12-hydroxyspirostan-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside], compound 13 is [(25S)-spirost-5-ene-3β27-diol 3-O-{6-deoxy-α-L-mannopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside}], compound 14 is [(25R,26R)-26-methoxyspirost-5-en-3β-ol 3-O-{6-deoxy-α-L-mannopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside}], compound 15 is [3β,25R,27(S)]-27-(4-carboxy-3-hydroxy-3-methyl-1-oxobutoxy)spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside], compound 16 is [3β,25R,27(S)]-27-[(3-hydroxy-5-methoxy-3-methyl-1,5-dioxopentyl)oxy]spirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside], compound 17 is β-D-Glucopyranoside, (3β,25R,26R)-17-hydroxy-26-methoxyspirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, compound 18 is (3β,25R,26R)-26-hydroxyspirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, compound 23 is 26-O-β-D-glucopyranosylnuatigenin 3-O-α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside Compound 24 is solanidine 3-O-α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, compound 25 is (3β,25S)-26-(β-D-glucopyranosyloxy)-22-hydroxyfurost-5, 25 (27) dien-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside, and compound 26 is solasodine 3-O-α-L-rhamnopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-β-D-glucopyranoside
- Where any preferred substituent (such as C1-6 alkyl, C1-6 hydroxyalkyl) is said to be composed of from 1 to 6 carbon atoms (ie C1-6) such substituents are more preferred with 1 to 4 carbon atoms (ie C1-4), are more preferred still with 1 or 2 carbon atoms (ie methyl or ethyl) and are most preferred with only one carbon atom (ie are in the methyl form). Likewise where partial substituents such as the C1-6 alkyl group or C1-6 alkoxy group of C1-6-alkoxy-C1-6-alkyl are said to be composed of from 1 to 6 carbon atoms (ie C1-6) such substituents are, independently one of the other, more preferred with 1 to 4 carbon atoms (ie C1-4), are more preferred still with 1 or 2 carbon atoms (ie methyl or ethyl) and are most preferred with only one carbon atom (ie are in the methyl form).
- Alkyl, alkenyl and alykynyl radicals may, where the number of carbons in the chain permits, be either straight-chain or branched chain. C1-6 alkyl radicals may be, for example, methyl, ethyl, n-propyl or isopropyl, n-butyl, isobutyl or tert-butyl, isopentyl, 2,2-dimethyl propyl, n-hexyl, isohexyl and 1,3-dimethylbutyl. C2-6 alkenyl radicals may be, for example, allyl, 1-methylprop-2-enyl, 2-methylprop-2-enyl, 2-methyl prop-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-but-3-enyl, 1-methyl-but-2-enyl, 3-methylbut-2-enyl; where the alkenyl radical consists of 2-8 carbon atoms, the possible arrangements include, in addition to those possible for radicals with 2-6 carbon atoms, the following preferred radicals 5-methyl-hex-5-enyl, 4-methyl-hex-5-enyl, 3,4-dimethyl-hex-2-enyl. C2-6 alkynyl may be, for example, propargyl, but-2-ynyl, but-3-ynyl, 1-methylbut-3-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 4-methyl-pent-2-ynyl. Preferably it is propargyl, 1-methylbut-3-ynyl, pent-2-ynyl, pent-4-ynyl or 4-methyl-pent-2-ynyl.
- A C1-6 hydroxyalkyl group may, where chemically possible, be either a C1-6 monohydroxyalkyl or a C1-6 dihydroxyalkyl group.
- Where moieties may be, in turn, substituted by a saccharide moiety it is preferred that the bond is through an oxygen to form a group such as:
- In the formula I the saccharide moiety A comprises multiple chiral centres. Thus each of the carbon atoms 1, 2, 3, 4 and 5 can, independently, be in the R or S form. Depending on the form of the anomeric carbon, A can, independently, be in either the alpha or beta anomeric form. For ring A the beta anomeric form is preferred. The saccharide moiety A can be in the D or L form; the D form is preferred. Depending on the arrangement around these chiral centres and the identity of the substituent R4, the monosaccharide A can take a number of forms. Thus for example when R4 is H, and R1, R2 and R3 are —OH the saccharide moiety may, for example, be arranged as arabinopyranose, lyxopyranose, ribopyranose or xylopyranose; preferably it is xylopyranose or ribopyranose; more preferably it is xylopyranose.
- When R4 is —CH3 and R1, R2 and R3 are —OH the saccharide moiety is a 6-deoxy hexopyranose, and may be arranged as 6-deoxyallose, 6-deoxyaltrose, 6-deoxygalactose(fucose), 6-deoxyglucose(quinovose), 6-deoxygulose, 6-deoxyidose, 6-deoxymannose(rhamnose) or 6-deoxytalose preferably it is 6-deoxyallose or quinovose; preferably it is quinovose.
- Where R4 is —CH2OH and R1, R2 and R3 are —OH the saccharide moiety is a hexopyranose and may be, for example, allose, altrose, galactose, glucose gulose, idose, mannose or talose; preferably it is allose, galactose or glucose, more preferably glucose. When R4 is —CH2OH, R2 and R3 are —OH, R1 is NR5R6 and R5 and R6 are H the saccharide may be arranged as a pyranosamine, for example as glucosamine, mannosamine or galactosamine. When R4 is —CH2OH, R2 and R3 are —OH, R1 is NR5R6 and R5 is H and R6 is —COCH3 the saccharide may be arranged as an N-acetylpyranosamine for example N-acetylglucosamine (GlcNAc), N-acetylmannosamine or N-acetylgalactosamine (GalNAc); most preferably it is GalNAc.
- Saccharides include, but are not limited to, monosaccharides, disaccharides, tri saccharides, tetrasaccharides and polysaccharides. Preferably sacchari de moieties are monosaccharides, but may be independently selected as di- or oligosaccharides.
- Monosaccharides include, but are not limited to, tetroses pentoses, hexoses and heptoses; tetroses pentoses and hexoses are preferred.
- Tetroses may be for example aldotetroses, such as erithrose and threose and aldoketoses erithrulose.
- Pentoses include, but are not limited to aldopentoses, such as arabinose, lyxose, ribose and xylose and ketopentoses such as ribulose and xylulose and deoxypentoses such as 2-deoxyribose and 3-deoxyribose. Preferred pentoses are xylose and arabinose. Pentoses may be in the furanose (eg arabinofuranose, lyxofuranose, ribofuranose and xylofuranose) or the pyranose (eg arabinopyranose, lyxopyranose, ribopyranose and xylopyranose) forms.
- Hexoses include, but are not limited to aldohexoses, such as, allose, altrose, galactose, talose, gulose, idose, mannose and glucose (preferred are glucose, mannose, galactose, altrose, allose idose and talose) and ketokexoses such as fructose, psicose, sorbose and tagatose.
- Hexoses may also be deoxy hexoses wherein an —OH group is replaced by an —H group at any position other than the bonded group. 6-deoxyhexoses are for example 6-deoxyallose, 6-deoxyaltrose, 6-deoxygalactose(fucose), 6-deoxyglucose(quinovose), 6-deoxygulose, 6-deoxyidose, 6-deoxymannose(rhamnose) or 6-deoxytalose. Deoxyhexoses may also be 2-deoxy, 3-deoxy, 4-deoxy and 5-deoxy hexoses. The oxygen may be lacking at more than one position. Examples of deoxyhexoses are—2-deoxy-glucose, 2-deoxygalactose, 4-deoxyfucose, 3-deoxygalactose, 2-deoxyglucose, 3-deoxyglucose, 4-deoxyglucose. Deoxyaldohexoses are preferred.
- Hexoses also include hexosamines such as galactosamine, glucosamine and mannosamine, n-acteyl hexosamines such as N-acetyl-galactosamine, N-acetylmannosamine and N-acetylglucosamine. Preferred hexoses are aldohexoses and deoxy hexoses, particularly preferred hexoses are glucose, galactose, quinovose, fucose and rhamnose.
- Hexoses may be in the furanose or pyranose form; preferably in the pyranose form.
- Other monosaccharides include uronic acids, for example fructuronic acid, galacturonic acid, iduronic acid, glucuronic acid, guluronic acid, mannuronic acid and tagaturonic acid; sedoheptulose, sialic acid, neuraminic acid, muramic acid, N-acetylneuraminic acid, N-acetylmuramic acid, O-acetylneuraminic acid, and N-glycolylneuraminic acid.
- Of hexoses, aldohexoses and deoxyhexoses (particularly deoxyaldohexoses) are preferred; of pentoses, aldopentoses and deoxy-pentoses (particularly deoxyaldopentoses) are preferred.
- Pharmaceutically acceptable esters of compounds of the formula 1 are for example, an ester with an aliphatic or aromatic carboxylic or sulphonic acid. Aliphatic carboxylic acids may be for example of up to 6 carbon atoms, for example a methyl, ethyl, tert-butyl succinyl or malyl. Aromatic carboxylic acids may for example benzoic acid, sulphonic acids may be methylsulphonic or p-toluenesulphonic acid, and include esters at any available esterifiable position.
- Pharmaceutically acceptable esters further include known compounds in which the sugar —OH groups are esterified with an aliphatic carboxylic acid of up to 6 carbon atoms. Also included are known esters at the carbon 26-position with compounds such as hydroxymethylgluteryric acid or its methyl ester (for example compound 19 and structure VI xxiv).
- Pharmaceutically acceptable ethers are, for example, with C1-6 hydroxyalkyl compounds which may be formed at any of the available —OH groups, for example on the saccharide moieties, or steroid moieties by converting one or more of the —OH groups to alkoxy groups (e.g. 61, 84, 85 incorporated herein by reference).
- A suitable pharmaceutically-acceptable salt form of the compounds of the formula I is, for example, an acid addition salt with an inorganic or organic acid, for example hydrochloric, hydrobromic, trifluoroacetic or maleic acid; or an alkali metal, for example sodium, an alkaline earth metal, for example calcium, or ammonium, for example tetra(2-hydroxyethyl)ammonium, salt.
- Compounds of the formula I can be extracted from a variety of plant species. Examples of sources of compounds of the invention and example purification protocols are given in the references of table 2 (which are incorporated herein by reference). Further sources of compounds of the invention and methods of isolation of such compounds are detailed in (27), particularly tables 2.2, 2.9, 2.10 and 2.11 and appendix 3—and references, therein which are incorporated herein by reference.
- Many compounds of the invention are hydroxylated steroids. It is known in the art that such compounds, when exposed to solvent such as alcohols during purification or preparation, may be converted to alkoxy derivatives or to other derivatives such as methylketals (which revert to the original compounds upon drying). Particularly furostanol compounds of the formula VIa, in which the carbon at the at the 22-position of the furostanol structure, is substituted by —OH, may be converted to alkoxy derivatives when exposed to alcohols. Notably such compounds may become methoxy derivatives when purified from plant sources using methanol-containing solvents. Alternatively they may be converted to the corresponding alkoxy by reflux in an appropriate anhydrous alcohol at elevated temperature, for example methanol (36). Such alkoxylated compounds are also compounds of the invention.
- Where the compounds of the invention are purified from natural sources it is preferred that they are used in isolated form. By isolated is meant that the compound is at least 1% pure, conveniently it is at least 10% pure, more conveniently at least 30% pure, preferably it is at least 50% pure more preferably it is at least 80% pure still more preferably it is at least 90% pure and most preferably it is at least 95% pure.
- The purity of the compound is conveniently expressed as a ratio of UV absorption associated with the compound to UV absorption associated with other material in the sample, conveniently at 205 nm. The purity of the compound may be measured for example using a chromatography system such as for example TLC or HPLC such as are described in the references herein, particularly in those references relating to the compound in question, or in applicants co pending application WO05/060977
- Alternatively, compounds of the invention may be synthesised via a number of routes known to the skilled worker. For example by glycosylation of appropriate aglycones.
- A number of suitable aglycones are available commercially, alternatively an suitable aglycone may be prepared, either by isolation from a natural source (27 and references therein), by deglycosylation of a suitable glycosylated compound (for example those compounds disclosed in (27) or herein), or by chemical synthesis from a variety of starting material that are readily available.
- Methods of synthesising Galβ1-3(6-deoxy)GalNAcα-conjugates are given in Paulsen et al (16) incorporated herein by reference. These methods may be adapted by the skilled worker in combination with other methods referenced herein to synthesize other compounds of the formula I.
- The skilled worker will be aware of many sources of spirostanol and furostanol aglycones suitable for preparing compounds for use in the invention. For example spirostanol aglycones wherein X═O or X═NH may be, for example, sarsapogenin, smilagenin, 12β-hydroxysmilagenin, Rhodeasapogenin, Isorhodiasapogenin, Samogenin, 12β-hydroxysamogenin, Markogenin, Yonogenin, Convallagenin A, Convallagenin B, Tokorogenin, Tigogenin, Neotigogenin, Gitogenin, Agigenin Digitogenin, Chlorogenin, Paniculogenin, (25R)-Spirostan-3β, 17α21-triol, Allogenin, (25R)-5α-Spirostan-2α,3β3,5α,6α-tetraol, (24S,25R)-5α-Spirostan-2α,3β,5α,6β,24-pentaol, Yamogenin Diosgenin, Yuccagenin, Lilagenin, Ruscogenin, (25S)-Ruscogenin, Neopraserigenin, Pennogenin, Isonuatigenin, Cepagenin, 24a-hydroxypennogenin, Ophiogenin, Sibiricogenin, Convallamarogenin, Neoruscogenin, Hecogenin, Neohecogenin, Manogenin, Sisalagenin, Solasodine, Soladulcidine, Tomatidine and 5-dehydrotomatidine.
- Deglycosylation of, for example steroidal glycosides, may be simply carried out by acid hydrolysis, for example in a 50:50 mix of 2N HCl: dioxane at 100° C. in a sealed tube for 4.5 hrs (36—incorporated herein by reference).
- Methods for the synthesis of a number of steroidal aglycones have been known for may years. For example synthesis of diosgenin, yamogenin, kryptogenin and isonarthogenin have been reported by the group of Kessar et al (58-60).
- General synthetic routes to a variety of tri saccharide substituted spirostanol saponins are known (28, 29, 31, 32—incorporated herein by reference). Methods of synthesis of spirostanol saponins having 2,4 branched oligosaccharide moieties are also known (33, 28, 34, 62—incorporated herein by reference). Methods of synthesis of furostanol saponins, synthesis of derivatised saponins and interconversion of spirostanol and furostanol saponins have also been devised (30, 32 to 34, 61 to 64—incorporated herein by reference). Furthermore, furostanol and spirostanol saponins can be inter converted using a β-glucosidase and pseudosaponins maybe cyclised to form the spirostanol derivative (63, 65—incorporated herein by reference).
- Combinatorial approaches to saponin synthesis have also been reported (66, 30—incorporated herein by reference).
- These references also provide information and further references on derivatisation of saccharide hydroxyl and hydroxyalkyl groups.
- As used herein the term aglycone refers to steroidal glycosides wherein the saccharide moieties are not present (e.g. page 29 line 18). The compounds may have other substituents at the position originally occupied by the saccharide moiety. Particularly aglycones that are furostanol saponins when not glycosylated may be in the ring closed state as the equivalent spirostanol compounds. Steroidal glycosides are compounds having a steroid or substituted steroid core, to which is attached one or more saccharide moieties. A steroidal sapogenin is the aglycone of a steroidal saponin. A steroidal saponin is a naturally derived steroidal glycoside.
- An anti cell adhesion agent is an agent that reduces the adhesion of cells to a substrate such as platelets or the lining of blood vessels or other tissues, an anti cell-cell interaction agent is an agent that reduces the interaction between cells. An anti cellular extravasation agent is an agent that reduces the passage of cells from the blood stream through the walls of blood vessels.
- The term “treating”, as used herein, includes treating as prophylaxis or treatment of a current or remitting illness.
- For the avoidance of doubt the term C1-6 acyl is —CO—C1-5-alkyl.
- In a second aspect of the invention is provided the use of compounds of the formula I in the manufacture of a medicament for the treatment of a condition associated with detrimental activity, particularly raised activity, of the enzyme core 2 GlcNAc-T.
- In a third aspect of the invention is provided the use of a compound of formula I as an anti cell adhesion agent, an anti cell-cell interaction agent or an anti cellular extravasation agent.
- In a fourth aspect of the invention is provided a pharmaceutical composition comprising compound of the formula I.
- Medicaments of the invention comprising compounds of the formula I will typically be prepared in a sterile and pyrogen free form. They can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- The medicament may be made up in liquid form in which case it will typically, in addition to the compound of the formula I, comprise a pharmaceutically acceptable diluent or it may be made up in solid form.
- For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
- Tablets for oral use may include the active ingredients mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Examples of suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are examples of suitable disintegrating agents. Binding agents include, for example starch and gelatine, while the lubricating agent, if present, may for example, be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with an enteric coating material, such as glyceryl mono stearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Capsules for oral use include hard gelatine capsules in which the active ingredient is mixed with a solid diluent, and soft gelatine capsules wherein the active ingredients is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil
- Formulations for rectal administration may for example be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may for example be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- In preparations for intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will typically be provided in a pharmaceutically acceptable diluent to provide sterile solutions, emulsions, liposome formulations or suspensions. Typically the preparation will be buffered to an appropriate pH and isotonicity. For example suitable diluents include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives include ethyl and n-propyl p-hydroxybenzoate.
- The isolated Core 2 GlcNAc-T inhibitors of the invention may also be incorporated into a food or beverage product.
- In general a suitable dose of Core 2 GlcNAc-T inhibitor will be in the range of 100 ng to 10 mg per kilogram body weight of the recipient per day, preferably in the range of 1 μg to 5.0 mg/kg/d. Typically the desired dose is presented once daily or several times a day in sub doses. These sub-doses may be administered in unit dosage forms, for example, containing 1 μg to 1500 mg, preferably 40 μg to 1000 mg, and most preferably 50 μg to 700 mg of active ingredient per unit dosage form.
- In the shorthand annotation:
- used in structures herein Glc is glucose and Rha is rhamnose. The annotation 2,3 and 2,4 denote the position of attachment of the saccharides to the central monosaccharide.
- The shorthand notation
- used in structures herein denotes the structure:
- The present invention will now be described further by reference to the following non-limiting Examples, Schemes and Figures. Further embodiments falling within the scope of the claim will- occur to those skilled in the art in the light of these.
-
-
TABLE 1 Example compounds of the invention. Table 1a 25 Bond Bond Compound Q A1 A2 A3 A4 A5 A6 A7 R/S a b 1 4- Me H H Glc OH H H R Double Single Rha 2 4- Me H H Glc Absent H H R Double Double Rha 3 4- Me H H Glc OH H H S Double Single Rha 4 4- Me H H Glc OMe H H R Double Single Rha 5 4- Me H H Glc OMe H H S Double Single Rha 6 4- Me H H Glc OH H H S Double Single Glc 7 4- Me H H Glc OH H H R Double Single Glc 8 4- Me H H Glc OMe H H R Double Single Glc 9 4- Me H OH —O•CO•CH3 OMe OH H R Single Single Glc 10 4- Me H OH —O•CO•CH3 OMe H H R Single Single Glc 21 4- Me H H Glc OH H H S Single Single Glc 25 4- ═CH2 H H Glc OH H H — Double Single Glc 27*** 3- Me H H Glc OH H H R Double Single Glc Table 1b Comp. Q A1 A2 A3 A4 A5 A6 25R/S Bond a 11 4-Rha Me H H H H H R Double 12 4-Glc Me H H H OH H R Single 13 4-Glc —CH2OH H H H H H S Double 14 4-Glc Me H H H H OMe R Double 15 4-Glc * H H H H H R Double 16 4-Glc ** H H H H H R Double 17 4-Glc Me H OH H H OMe R Double 18 4-Glc Me H H H H OH R Double 19 4-Glc Me H H H H H S Double 20 4-Glc Me H H H H H R Double 22 4-Glc Me H H H H H S Single Table 1c Further example compounds of the invention Compound Structure 23 24 26 ***comparative compound Substituent “*” = Substituent “**” = -
TABLE 2 Key to example compounds of the invention and references Example Compound references Compound name 1 36 Protodioscin 2 37 Pseudoprotodioscin 3 36 Protoneodioscin 4 36 Methylprotodioscin 5 36 Methylprotoneodioscin 6 17 Trigoneoside IVa 7 22, 17 Glycoside F, protodeltonin, deltoside, 8 42 No name 9 19 Pardarinoside C 10 19 Pardarinoside D 11 39 Dioscin 12 38 Not named 13 20, 40, 41, 42 Not named 14 40, 42 Not named 15 40, 41, 20, 21 Not named 16 41, 20 Not named 17 42 Not named 18 43 Not named 19 26, 42, 25 Balanitin VI 20 24, 71 Deltonin 21 18, 23 Shatavarin I 22 18, 23 Shatavarin IV 23 20 Not named 24 21 Not named 25 WOO5060977 Not named 26 20 Not named 27 36 Protogracillin*** ***comparative example compound. - All compounds used herein were supplied by Chromadex Inc. 2952 S. Daimler Street Santa Ana Calif. 92705. Compounds used were at least 88% pure
-
TABLE 4 Purity of compounds used Compound Number Purity Protodioscin 1 93.3% Pseudoprotodioscin 2 88.6% Dioscin 11 90.8% Trigoneoside IVa 6 89% Glycoside F 7 80.3% Shatavarin I 21 >95% ***Protogracillin 26 98.8% Purity was determined by HPLC using UV absorption at 205 nm
1a. Cell Culture - The human leukocytic cell-line (U937) was cultured in RPMI supplemented with 10% foetal calf serum, 2 mM glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin.
- 1b. Assay of Core 2 GlcNAc-T Activity
- (i). Glucose induction of Core 2 GlcNAc-T leukocytes (U937 cells) were exposed to normal glucose (5.8 mM) or high glucose (15 mM) for 24 hours at 37° C. After incubation, the cells maybe lysed and frozen at −20° C. until used for the measurement of core 2 GlcNAc-T or used immediately.
- (ii). TNF-α induction of core 2 GlcNAc-T. Human leukocytes(U937 cells) were exposed to human recombinant TNF-alpha (8 pg/ml) in the presence and absence of test compounds After 24 h incubation, the activity of core 2 GlcNAc-T was measured, and expressed as pmoles/h/mg protein
- (iii). Cell free assay of core 2 GlcNAc-T in cell free assays of core 2 GlcNAc-T Heart lysates from either from TNF-alpha over expressing transgenic mice (female, B6.SJL-Tg (TNF) supplied by Taconic-M+B, Bomholtveg 10, 8680 Ry, Denmark) or from BB rats (Festing 1979) was exposed to various concentrations of test compound for 1 h at 37° C. Activity of core 2 GlcNAc-T was measured, and expressed as pmoles/h/mg protein.
- 1c. Measurement of Core 2 GlcNAc-T Activity
- To measure core 2 GlcNAc-T activity, leukocytes were washed in PES, frozen and lysed in 0.9% Triton X-100 at 0° C. The activity of core 2 GlcNAc-T was measured as described below. Cell free assays are preformed by substituting heart lysates for cell lysates.
- The reaction was performed in a reaction mixture containing 50 mM 2(N-morpholino)ethanesulfonic acid (MES, Sigma, Dorset, UK), pH 7.0, 1 mM UDP-6 ['H]-N-acetylglucosamine (16,000 dpm/nmol, NEN Life Science Products, Hounslow, UK), 0.1 M GlcNAc (Sigma, Dorset, Okla.), 1 mM Galβ1-3GalNAcα-p-nitrophenol (Sigma, Dorset, UK) as substrate, and 16 μl of lysate (100-200 μg protein) for a final volume of 32 μl. After incubating the mixture for 1 hour at 37° C., the reaction was terminated with 1 ml of ice-cold distilled water and processed on a C18 Sep-Pak column (Waters-Millipore, Watford, UK). After washing the column with 20 ml of distilled water, the product was eluted with 5 ml of methanol. The radioactivity of the samples was counted in a liquid scintillation β-counter (LKB-Wallac, London, UK). Endogenous activity of core 2 GlcNAc-T was measured in the absence of the added acceptor. The specific activity was expressed as pmoles/h/mg of cell protein. In each case, the protein concentration was determined with BioRad protein assay (BioRad, Hertfordshire, UK). Results are shown in table 5.
-
TABLE 5 Approximate Ic50 values (nM) for example compounds Cell free Cell based Compound Number assay assay Protodioscin 1 20** a Pseudoprotodioscin 2 35* 50 Dioscin 11 40* 75 Trigoneoside IVa 6 0.9* 75 Glycoside F 7 5** b Shatavarin I 21 1* 0.75 Shatavarin IV 22 c** † ***Protogracillin 26 3* 0.25 *Cell free assays were carried out on heart lysates of TNF-α mice as described above. **Cell free assays were carried out on heart lysates of BB rats as described above. a 33% inhibition at 20 nM b 100% inhibition at 22 nM n BB rat heart lysate c 89% inhibition at 22 nM in BB rat heart lysate † no activity detected at 22.5 nM ***comparative compound - Compound C (at 20 ng/ml) was found to inhibit Core 2 GlcNAc-T approximately 98.5% compared to controls, in TNF-□ treated Human leukocytes (U937 cells). The sample of compound C was approximately 82.5% pure by HPLC at 205 nM
- The approximate IC50 of Trigoneoside IVa was found to be between 0.25 nM and 0.9 nM in cell free systems. Further analysis of a sample prepared according to applicants co pending WO05/060977 indicates that it contains approximately 7.5% protodioscin and 9% Trigonelloside C (17).
- The IC50 of Glycoside F was found to be approximately 5 nM. Further analysis of the preparation indicates that it contains a small amount of Trigonelloside C.
- The IC50 of Protodioscin (93.3% pure) produced as described in applicants co pending WO05/060977 was found to be approximately 20 nM. The sample contained 1.5% Trigoneoside IVa. A sample prepared from Tribulus terrestris (Chromodex Inc. 2952 S. Daimler Street Santa Ana Calif. 92705), which was 97% pure, and had an NMR spectrum consistent with protodioscin, appeared to demonstrate no activity at concentrations of 50 μM. Thus Trigoneoside IVa activity could account for at least some of the activity seen in the protodioscin sample prepared as per WO05/060977.
- Trigonelloside C is similar to Protodioscin but is the opposite isomer at carbon 25. A preparation of this compound according to co pending WO05/060977 was 98.2% pure and contained no measurable quantity of other Core 2 GlcNAc-T inhibitors. A preparation of Trigonelloside C prepared according to WO05/060977 inhibited Core 2 GlcNAc-T 69% at 2.5 nM.
-
- 1. Ellies L. G. et al., Immunity 9, 881-890 (1998)
- 2. Brockhausen I. et al., Cancer Res. 51, 1257-1263 (1991)
- 3. Renkonen J. et al., APMIS 109, 500-506 (2001)
- 4 Machida E. et al., Cancer Res. 61, 2226-2231 (2001)
- 5. Dalziel M. et al., Biol. Chem. 276, 11007-11105 (2001)
- 6. Perandio M. et al., Blood 97, 3812-3819 (2001)
- 7. Yousefi S. et al., J. Biol. Chem. 266, 1772-1782 (1991)
- 8. Higgins E. A. et al., J. Biol. Chem. 266, 6280-6290 (1991)
- 9. Piller F. et al., J. Biol. Chem. 263, 15146-15150 (1988)
- 10. Koya D. et al., FASEB J. 13, 2329-2337 (1999)
- 11. Nishio Y. et al., J. Clin. Invest. 96, 1759-1767 (1995)
- 12. Tsuboi S. et al., Bioassays 23, 46-53 (2001)
- 13. Tsuboi S. et al., EMBO J. 16, 6364-6373 (1997)
- 14. Tsuboi S. et al., J. Biol. Chem. 273(46), 30680-30687 (1998)
- 15. Kuhns W. et al., Glycoconjugate Journal 10 381-394 (1993)
- 16. Paulsen H. et al., Leibigs Ann. Chem. 747-758.(1992)
- 17. Yoshikawa M. et al., Heterocycles 47, 397-405 (1998).
- 18. Ravikumar P. R. et al., Indian J. Chem. 26B, 1012-1017 (1987).
- 19. Shimomura H. et al., Phytochemistry 28, 3163-3170 (1989).
- 20. Mimaki Y and Sasheda Y. Chem. Pharm. Bull. 38(11), 3055-9(1990).
- 21. Sashida Y. et al., Chem. Pharm. Bull. 39(9), 2362-8(1991)
- 22. Akhov L. S. et al., J. Agric. Food Chem. 47(8), 3193-3196 (1999)
- 23. Joshi J. et al., Indian J. Chem. 27B, 12-16 (1988).
- 24. Vasil'eva I. S. et al., Appl. Biochem. Microbiol. 31, 206-209 (1995).
- 25. Sharma et al., Phytochemistry. 33(3):683-6. (1993).
- 26. Petit G. et al., Journal of natural products 54, 1491-1502.
- 27. Hostettman K. and Marston A. Saponins. Cambridge University Press UK. (1995).
- 28. Deng S et al., Carbohydr Res. 30;317(1-4):53-62. (1999).
- 29. Li B et al., Carbohydr Res.; 9;331(1):1-7. (2001).
- 30. Yu B et al., J Comb Chem.; 3(5):404-6. (2001).
- 31. Yu B., et al., Tetrahedron letters, 42, 77-79 (2001).
- 32. Yu B et al., J Org Chem.; 13;67(25):9099-102 (2002).
- 33. Cheng M S et al., J Org Chem.; 2;68(9):3658-62 (2003)
- 34. Du Y et al., Org Lett.; 2;5(20):3627-30.(2003).
- 35. Mimaki Y. et al., Chem Pharm Bull (Tokyo). 46(11):1829-32(1998).
- 36. Hu K. et al Planta Medica, 63(2), 161-165 (1997).
- 37. Dong M. et al., Planta Med. 67(9):853-7 (2001).
- 38. Ori K. et al. Phytochemistry. 31(8):2767-75 (1992).
- 39. Kawasaki T. et al., Chemical & Pharmaceutical Bulletin, 22(9), 2164-75 (1974).
- 40. Mimaki Y. et al Phytochemistry 37(1):227-32 (1994).
- 41. Nakamura O. et al., Phytochemistry. 36(2):463-7 (1994).
- 42. Mimaki Y. et al., Chem Pharm Bull (Tokyo). 46(11):1829-32 (1998).
- 43. Haladova M. et al., Pharmazie, 54(2), 159-160 (1999).
- 44. Liu H. et al,. Chem. Pharm. Bull. 51(9), 1089-1091 (2003).
- 45. Hindsgaul O. et al., J Biol Chem. 266(27):17858-62 (1991).
- 46. Toki D. et al, Biochem Biophys Res Commun. 198(2):417-23 (1994).
- 47. Kumar R. et al., Blood. 15;88(10):3872-9 (1996).
- 48. Stoica S. et al., J Heart Lung Transplant. 24(5):593-601 (2005).
- 49. Dedrick R. L. et al., Expert Opin Biol Ther. 3(1):85-95 (2003).
- 50. Hansen A. et al., J Am Coll Cardiol. 18;44(4):887-91 (2004).
- 51. Wang K. et al., Thromb Haemost. 88(1):149-54 (2002).
- 52. Tanguay J. et al., Thromb Haemost. 91(6):1186-93 (2004).
- 53. Bienvenu J. et al., Circulation. 27;103(8):1128-34 (2001).
- 54. Inoue T. et al., J Leukoc Biol. 77(3):287-95 (2005).
- 55. Rijcken E. et al., Am J Physiol Gastrointest Liver Physiol. 287(1):G115-24 (2004).
- 56. Strauss E. et al., Invest Ophthalmol Vis Sci. 40(7):1336-421 (1999).
- 57. Hickey M. et al., J Immunol. 168(9):4728-36 (2002).
- 58. Kessar S. et al., Tetrahedron.; 24(2):905-7 (1968).
- 59. Kessar S. et al., Tetrahedron 24(2):899-904 (1968).
- 60. Kessar S. et al., Tetrahedron. 24(2):887-92 (1968) .
- 61. Li M et al., Carbohydr Res. 20; 338(2): 117-21 (2003).
- 62. Lehmann M. et al, Carbohydr Res. 337(21-23): 2153-9 (2002).
- 63. Tobari A. et al., Eur J Med Chem. 35(5): 511-27 (2000).
- 64. Wang S. M. et al., Steroids. 69(10): 599-604 (2004).
- 65 Inoue K. et al., Phytochemistry 41(3), 725-7(1996).
- 66. Lautrette S. et al., Chem Commun (Camb). 7;(5): 586-7 (2004).
- 67. Chow F. et al., Nephrol Dial Transplant. 19(12):2987-96 (2004).
- 68. Myers D. et al., Thromb Haemost. 87(3):374-82 (2002).
- 69. Lanteri M. et al., Glycobiology. 13(12):909-18 (2003).
- 70. Yago T. et al., J Biol Chem. 26;278(39):37987-97 (2003).
- 71. Vasil'eva I. et al., Prikl Biokhim Mikrobiol. 20(3):404-6 (1984).
- 72. Akhov L. S. et al Proc. Phytochem. Soc. Euprope 45, 227-231 (2000).
- 73. Kim S. Y. et al Arch. Chem. Res. 22 (3) 313-316 (1999).
- 74. Vasil'eva I. S. and Paseshnichenko V. A. Adv. Exp. Med. Biol. 404, 15-22 (1996).
- 75. Oda K et al Biol Chem. 381(1):67-74 (2000).
- 76. Li X. et al Phytochemistry 29(12), 3893-8 (1990).
- 77. Hernandez et al bioorganic and med. chem. 12(16) 4423-4429 (2004).
- 78. Renault J. et al, Phytochemistry, 44(7), 1321-1327 (1997).
- 79. Kim S Y et al Arch Pharm Res. 22(3):313-6 (1999).
- 80. Matsuda H et al Bioorg Med Chem Lett. 24;13(6):1101-6 (2003).
- 81. Dang B. et al J Leukoc Biol. 72(4):702-10 (2002).
- 82. Theoret J. et al J Pharmacol Exp Ther. 298(2):658-64 (2001).
- 83. Festing M. F. W. (Ed.). Inbred strains in biomedical research. The Macmillan Press LTD, London (1979). ISBN 0-333-23809-5.
- 84. Purdie and Irvine, J. Chem. Soc. 87, 1022 (1905).
- 85. Haworth and Hirst, J. Chem. Soc. 119, 193 (1921).
- 86. Zheng Q. et al Steroids, 69(2), 111-119 (2004).
- 87. Yoshikawa K et al. Chemical & Pharmaceutical Bulletin, 40(9), 2287-91 (1992).
- 88. Yoshikawa K. et al Chemical & Pharmaceutical Bulletin, 40(9), 2275-8 (1992).
- 89. Chen C. et al Yunnan Zhiwu Yanjiu, 9(4), 495-502 (1987).
- 90. Fujita S. et al Phytochemistry, 38(2), 465-72 (1995).
- 91. Yin F. et al J. Nat. Products, 67(6), 942-952 (2004).
- 92. Sang S. Phytochemistry, 52(8), 1611-1615 (1999).
- 93. Chen C. et al Yunnan Zhiwu Yanjiu, 6(1), 111-17 (1984).
Claims (29)
1-27. (canceled)
28. A food or beverage product into which has been incorporated a compound of the formula (I) isolated to at least 1% purity
wherein
R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1;
R2 is H, —OH, C1-6 alkoxy or Sac 2;
R3 is H, —OH, C1-6 alkoxy or Sac 3;
R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl;
R5 is H, C1-6 alkyl or C1-6 acyl;
R6 is H, C1-6 alkyl or C1-6 acyl;
Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and
Z is a steroid moiety;
or a pharmaceutically acceptable salt, ether or ester form thereof.
29. A food or beverage product according to claim 28 in which R1 is —OH, or Sac 1.
30. A food or beverage product according to claim 28 in which Sac 1 is selected from a pentose, a deoxy-aldohexose and an aldohexose.
31. A food or beverage product according to claim 28 in which R2 is —OH.
32. A food or beverage product according to claim 28 in which R3 is Sac 3.
33. A food or beverage product according to claim 28 in which Sac 3 is selected from a pentose, a deoxy-aldohexose and an aldohexose.
34. A food or beverage product according to claim 28 in which Sac 3 is selected from a pentose, and an aldohexose.
35. A food or beverage product according to claim 28 in which Sac 3 is an aldohexose.
36. A food or beverage product according to claim 28 in which Sac 3 is glucose.
37. A food or beverage product according to claim 28 in which R1 is —OH, C1-6 alkoxy, —NR5R6; R2 is Sac 2 and R3 is —OH.
38. A food or beverage product according to claim 37 in which R1 —NR5R6.
39. A food or beverage product according to claim 28 in which R4 is H, —CH2OH or —CH3.
40. A food or beverage product according to claim 28 in which R5 is H or —CH3.
41. A food or beverage product according to claim 28 in which R6 is H or —COCH3.
42. A food or beverage product according to claim 28 in which the steroid group, Z, is of the formula IV:
wherein:
R7 and R14 are independently selected from H and —OH;
R8 is C1-6 alkyl;
R9, R11, R16 are independently selected from H and C1-6 alkyl;
R10 is H or —OH or the H normally also present is absent and R10 is ═O;
R12 is H, —OH or C1-6acyl or a group selected from VII a or VII b;
R13 is H;
R15 is H, —OH or C1-6 alkyl or R13 and R15 taken together form a —CH2—CH2— group;
R17 is H, C1-6 alkyl or C1-6 hydroxyalkyl;
R22 is H or —OH;
R29 is C1-6 alkyl;
R30 is C1-6 hydroxyalkyl;
R31 is C1-6 alkyl, C1-6 hydroxyalkyl or C1-6 alkyl substituted by Sac 5;
R32 is C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl; and
43. A food or beverage product according to claim 42 in which the steroid moiety Z incorporates a further group selected from the groups consisting of groups VI (a) to VI (e):
wherein:
R18, R23, R27 and R33 are independently selected from C1-6 alkyl;
R19 and R24 are independently selected from H and —OH;
R20 is H, —OH or C1-6 alkoxy or R19 and R20 taken together represent the second bond of a double bond joining adjacent carbon atoms;
R21 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or a C1-6 alkyl or C2-6 alkenyl group substituted by one or more groups selected from the group consisting of —OH, C1-6 alkoxy and Sac 4;
R25 is C1-6 alkyl, C1-6 hydroxyalkyl or ═CH2;
R26 is —OH;
R28 is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl;
R34 is C1-6 hydroxyalkyl or C1-6 alkyl substituted by Sac 6;
R35 is C1-6 alkyl;
Sac 4, Sac 5 and Sac 6 are independently selected saccharides;
X is either O or NH.
44. A food or beverage product according to claim 43 in which R21 is C1-6 alkyl, C2-6 alkenyl, C1-6 alkynyl or a C1-6 alkyl group substituted by one or more groups selected from the group consisting of —OH, C1-6 alkoxy and Sac 4.
45. A food or beverage product according to claim 43 in which R21 is C2-6 alkenyl, or a C1-6 alkyl group substituted by one or more groups selected from the group consisting of —OH, C1-6 alkoxy and Sac 4.
46. A method according to claim 42 in which R21 is C2-6 alkenyl or a C1-6 alkyl group substituted by one or more groups selected from the group consisting of —OH, —OCH3 and Sac 4.
47. A food or beverage product according to claim 42 in which Sac 4 is glucose.
48. A food or beverage product according to claim 42 in which R31 is —CH3 or —CH2-Sac 5.
49. A food or beverage product according to claim 42 in which Sac 5 is glucose.
50. A food or beverage product according to claim 42 in which R34 is —CH2-Sac-6.
51. A food or beverage product according to claim 42 in which Sac 6 is glucose.
52. A food or beverage product according to claim 42 in which X is O.
53. A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T comprising administering to the subject a food or beverage product into which has been incorporated an isolated compound of the formula (I) according to claim 28 .
54. A method according to claim 53 in which the condition to be treated is selected from the group consisting of vascular diseases, autoimmune and inflammatory conditions.
55. A method according to claim 54 in which the condition to be treated is selected from the group consisting of:
multiple sclerosis, myopathy, retinopathy, nephropathy, atherosclerosis, asthma, rheumatoid arthritis, inflammatory bowel disease, transplant rejection, ischemia reperfusion injury, restenosis, ileitis, Crohn's disease, thrombosis, cholitis, lupus, frost bite injury, acute leukocyte mediated lung injury, traumatic shock, septic shock, nephritis, psoriasis, cholicytitis, cirrhosis, diverticulitis, fulminant hepatitis, gastritis, gastric and duodenal ulcers, hepatorenal syndrome, irritable bowel syndrome, jaundice, pancreatitis, ulcerative cholitis, Wiskott-Aldrich syndrome T-cell activation, AIDS, infection with viruses, bacteria, protozoa and parasites adapted to use core 2 derived glycans, cancer and cancer metastasis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/588,606 US20100048495A1 (en) | 2005-07-06 | 2009-10-21 | Core 2 GlcNAc-T inhibitors III |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513881.3 | 2005-07-06 | ||
GBGB0513881.3A GB0513881D0 (en) | 2005-07-06 | 2005-07-06 | Core 2 GLCNAC-T Inhibitors III |
US11/481,256 US7998943B2 (en) | 2005-07-06 | 2006-07-06 | Core 2 GlcNAc-T inhibitors III |
US12/588,606 US20100048495A1 (en) | 2005-07-06 | 2009-10-21 | Core 2 GlcNAc-T inhibitors III |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/481,256 Continuation US7998943B2 (en) | 2003-12-22 | 2006-07-06 | Core 2 GlcNAc-T inhibitors III |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100048495A1 true US20100048495A1 (en) | 2010-02-25 |
Family
ID=34856778
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/481,256 Expired - Fee Related US7998943B2 (en) | 2003-12-22 | 2006-07-06 | Core 2 GlcNAc-T inhibitors III |
US12/588,606 Abandoned US20100048495A1 (en) | 2005-07-06 | 2009-10-21 | Core 2 GlcNAc-T inhibitors III |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/481,256 Expired - Fee Related US7998943B2 (en) | 2003-12-22 | 2006-07-06 | Core 2 GlcNAc-T inhibitors III |
Country Status (9)
Country | Link |
---|---|
US (2) | US7998943B2 (en) |
EP (4) | EP1909802B1 (en) |
JP (1) | JP2009500386A (en) |
CN (1) | CN101252939B (en) |
AU (1) | AU2006264644B8 (en) |
CA (1) | CA2614017A1 (en) |
GB (1) | GB0513881D0 (en) |
MX (1) | MX2008000256A (en) |
WO (1) | WO2007003957A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0513888D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
MX2009001163A (en) * | 2006-08-03 | 2009-03-31 | Oncology Res Int Ltd | Methods and compositions for promoting activity of anti-cancer therapies. |
BRPI0715073A8 (en) * | 2006-08-03 | 2018-04-10 | Oncology Res International Limited | methods and compositions for inhibiting angiogenesis |
US20090012014A1 (en) * | 2007-07-02 | 2009-01-08 | Indus Biotech Pvt. Ltd | Compound, Composition and a Process Thereof |
EP2285821B1 (en) * | 2008-06-17 | 2014-12-17 | Pawan Kumar Goel | A novel process for extraction of furostanolic saponins from fenugreek seeds |
US20190388548A1 (en) * | 2018-06-26 | 2019-12-26 | Tzu Chi University | Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death |
CN113181192B (en) * | 2021-04-16 | 2023-11-07 | 陕西中医药大学 | Application of pennogenin compound |
Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1237583A (en) * | 1916-07-22 | 1917-08-21 | Lucinda Taylor | Letter-folder. |
US1243129A (en) * | 1915-11-10 | 1917-10-16 | Victor S Bauder | Silo and door therefor. |
US1361111A (en) * | 1918-10-26 | 1920-12-07 | Claude L Steele | Water-motor |
US2335436A (en) * | 1940-04-15 | 1943-11-30 | Ampro Corp | Cinematograph |
US5104856A (en) * | 1990-11-09 | 1992-04-14 | Uab Research Foundation | Heparan sulfate biosynthesis primers |
US5360733A (en) * | 1992-10-01 | 1994-11-01 | La Jolla Cancer Research Foundation | Human β1-6 n-acetylglucosaminyl transferase |
US5461879A (en) * | 1994-04-19 | 1995-10-31 | Carrier Corporation | Air conditioner condensate slinger |
US5470879A (en) * | 1992-09-07 | 1995-11-28 | Laboratories Monal | Treatment of non-insulin-dependent diabetes |
US5486510A (en) * | 1991-03-28 | 1996-01-23 | Rooperol (Na) Nv | Method and compositions for modulating or control of immune responses in humans |
US5589832A (en) * | 1994-12-02 | 1996-12-31 | Lucent Technologies Inc. | Low noise non-sampled successive approximation |
US5638778A (en) * | 1995-12-06 | 1997-06-17 | James; Robert G. | Opposed piston swash plate engine |
US5827884A (en) * | 1995-09-15 | 1998-10-27 | Omp Acquisition Corporation | Skin peel maintenance composition and method |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US5880091A (en) * | 1989-03-08 | 1999-03-09 | The Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US5886029A (en) * | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
US5952393A (en) * | 1998-02-12 | 1999-09-14 | Sorkin, Jr.; Harlan Lee | Composition for reducing serum cholesterol levels |
US5958770A (en) * | 1990-01-18 | 1999-09-28 | Cham; Bill Elliot | Glycoalkaloids |
US5965449A (en) * | 1996-07-03 | 1999-10-12 | Forbes Medi-Tech, Inc. | Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders |
US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
US6042834A (en) * | 1997-01-29 | 2000-03-28 | Baraka; Mohamed Wasif | Herbal composition for diabetes and method of treatment |
US6087353A (en) * | 1998-05-15 | 2000-07-11 | Forbes Medi-Tech Inc. | Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like |
US6197832B1 (en) * | 1999-09-14 | 2001-03-06 | Harlan Lee Sorkin, Jr. | Composition for reducing serum cholesterol levels |
US6294157B1 (en) * | 1999-10-14 | 2001-09-25 | L'oreal | Composition containing sapogenin |
US20020016314A1 (en) * | 2000-01-31 | 2002-02-07 | Schersl Endre Markovits | Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides |
US6346267B1 (en) * | 2000-07-07 | 2002-02-12 | Wakunaga Of America Co., Ltd. | Composition and method for treatment of symptoms associated with insufficient estrogen production |
US20020018811A1 (en) * | 2000-05-15 | 2002-02-14 | Penteado Roberto Luiz Bruno | Application of phytosteroids(and isomers thereof), folic acid, cyanocobalamine and pyridoxine in dietetic (alimentary) fibers |
US6383514B1 (en) * | 1996-11-28 | 2002-05-07 | Henkel Kommanditgesellschaft Auf Aktien | Use of mixtures of active substances for the production of hypocholesterolemic agents |
US6407085B1 (en) * | 1997-01-16 | 2002-06-18 | Horst Kief | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
US20020098563A1 (en) * | 1999-02-03 | 2002-07-25 | Bozena Korczak | Novel core 2 beta-1,6-N-acetylglycosaminyltransferase gene |
US20020156051A1 (en) * | 1999-06-23 | 2002-10-24 | Forbes Medi-Tech Inc. | Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders |
US20020193317A1 (en) * | 1998-03-26 | 2002-12-19 | Zongqin Xia | Steroidal sapogenins and their derivatives for treating alzheimer's disease |
US20030004147A1 (en) * | 1999-03-26 | 2003-01-02 | Paul Barraclough | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
US20030098563A1 (en) * | 2001-11-28 | 2003-05-29 | The Timken Company | Hub assembly with driven hub |
US20030156051A1 (en) * | 2000-09-11 | 2003-08-21 | Broadcom Corporation | Sigma-delta digital-to-analog converter |
US6635461B1 (en) * | 1999-08-24 | 2003-10-21 | Glycozym Aps | UDP-N-acetylglucosamine: galactose-β1, 3-N-acetylgalactosamine-α-R/(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3 |
US20040038923A1 (en) * | 2000-10-06 | 2004-02-26 | Marth Jamey D. | Blocking inflammation by inhibiting sialylation |
US20040049352A1 (en) * | 2000-05-10 | 2004-03-11 | Isabelle Andre | Designing modulators for glycosyltransferases |
US6787151B2 (en) * | 2001-08-10 | 2004-09-07 | Lipton, Division Of Conopco, Inc. | Composition for lowering blood cholesterol |
US20040220115A1 (en) * | 1999-04-09 | 2004-11-04 | Cham Bill E | Medicinal compositions and their method of preparation |
US20040249138A1 (en) * | 2001-09-28 | 2004-12-09 | Chris Lawson | Solvent extraction process |
US6933291B2 (en) * | 2000-12-01 | 2005-08-23 | N.V. Nutricia | Cholesterol lowering supplement |
US6998501B1 (en) * | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
US20060052351A1 (en) * | 2003-02-10 | 2006-03-09 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress |
US20070107292A1 (en) * | 2004-05-10 | 2007-05-17 | Gyro Snipe Ltd. | Retro-reflective aiming means |
US20070254847A1 (en) * | 2004-09-30 | 2007-11-01 | Chengdu Di'ao Pharmaceutical Group Co., Ltd. | Pharmaceutical Composition Containing Steroidal Saponins, the Preparation Method and Use Thereof |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU833254A1 (en) | 1979-03-15 | 1981-05-30 | Ордена Ленина Институт Биохимииим. A.H.Баха Ah Cccp | Method of obtaining deltonin |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
IT1195849B (en) * | 1986-07-01 | 1988-10-27 | Sigma Tau Ind Farmaceuti | TRITERPENIC SOAPS WITH ANTI-INFLAMMATORY, MUCOLITIC AND ANTI-EDEMIGEN ACTIVITY, PROCEDURE FOR THEIR OBTAINING AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM |
RU2027434C1 (en) * | 1988-08-16 | 1995-01-27 | Научно-Исследовательский Институт Трансплантологии И Искусственных Органов | Immunomodulating drug |
JP3123745B2 (en) | 1990-03-16 | 2001-01-15 | 三和生薬株式会社 | Anticancer drug |
US5461143A (en) * | 1991-03-18 | 1995-10-24 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
DE4303214A1 (en) | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones |
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
US5723456A (en) | 1993-12-07 | 1998-03-03 | Eli Lilly & Company | Therapeutic treatment for cardiovascular diseases |
EP0817627B1 (en) | 1993-12-23 | 2005-03-09 | Eli Lilly And Company | Protein kinase c inhibitors |
IL108583A (en) | 1994-02-07 | 1997-06-10 | Yissum Res Dev Co | Galactomannan emulsions and comestible products containing the same |
US5491242A (en) | 1994-06-22 | 1996-02-13 | Eli Lilly And Company | Protein kinase C inhibitors |
CN1138984A (en) * | 1995-06-26 | 1997-01-01 | 军事医学科学院放射医学研究所 | Anti-thrombosis glucoside medicine |
AU723262B2 (en) | 1995-08-03 | 2000-08-24 | Board Of Regents Of The University Of Oklahoma, The | Peptide and O-glycan inhibitors of selectin mediated inflammation |
FI107015B (en) | 1996-08-09 | 2001-05-31 | Raisio Benecol Oy | Mixture of vegetable stanol fatty acid esters and their use in food |
ATE210673T1 (en) | 1996-09-30 | 2001-12-15 | Bayer Ag | GLYCOCONJUGATES OF MODIFIED CAMPTOTHECINE DERIVATIVES (20-O LINKAGE) |
US6131578A (en) * | 1996-10-02 | 2000-10-17 | King; George L. | Inhibitors of UDP-G1cNAc:Ga1β1-3Ga1NAcαR β1-6 N-acetylglucosaminyltransferase (core 2 G1cNAc-T) and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes |
CA2186987A1 (en) | 1996-10-02 | 1998-04-02 | George L. King | Inhibitors of core 2 glcnac-t and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes |
EP1021177A4 (en) | 1997-02-04 | 2002-05-15 | John V Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
CA2206157C (en) * | 1997-05-26 | 2000-06-13 | Cheng, Peter | Method of extraction of commercially valuable fractions of fenugreek |
CN1131237C (en) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | Usage of steroi saponin for preventing and curing senile dementia and new steroid saponin |
WO1999025197A1 (en) | 1997-11-18 | 1999-05-27 | Nutricept, Inc. | Fenugreek compositions having reduced taste and odor and methods of use |
AU2660099A (en) | 1998-02-06 | 1999-08-23 | Medical Isotopes Inc. | Readily absorbable phytosterols to treat hypercholesterrolemia |
WO1999053925A1 (en) | 1998-04-17 | 1999-10-28 | Medical Isotopes Inc. | Phytosterol formulations to lower cholesterol absorption |
CN1237583A (en) | 1998-06-01 | 1999-12-08 | 沈阳药科大学 | Steroid saponins compound for curing cancer and its preparation method |
CN1092203C (en) * | 1998-07-22 | 2002-10-09 | 北京鑫利恒医药科技发展有限公司 | Process for extracting ginsenoside Re, and use of medicine thereof |
CA2347940A1 (en) * | 1998-11-21 | 2000-06-02 | The Regents Of The University Of California | Use of core 2 glcnac transferase inhibitors in treating inflammation |
WO2000052029A1 (en) | 1999-03-04 | 2000-09-08 | Eugene Science Inc. | Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same |
AUPP968699A0 (en) | 1999-04-09 | 1999-05-06 | Cura Nominees Pty Ltd | Therapeutic compositions and method for their preparation |
DE60017128T2 (en) | 1999-06-21 | 2006-01-26 | Forbes Medi-Tech Inc., Vancouver | Aromatic and heterocyclic derivatives of phytosterols and / or phytostanols for the treatment of vascular diseases |
CN1243129A (en) | 1999-07-20 | 2000-02-02 | 沈阳药科大学 | Steroid oside compound for treating cancer and preparation method thereof |
GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
AU2004205302A1 (en) * | 1999-10-26 | 2004-09-23 | Pingtel Corp. | Distributed communications network including one or more telephony communication devices having programmable functionality |
WO2001032679A2 (en) * | 1999-11-01 | 2001-05-10 | Forbes Medi-Tech Inc. | Novel glycosides comprising pentose mono-, di-, tri-, or oligosaccharides and phytosterols and/or phytostanols |
CN1302811A (en) * | 2000-01-03 | 2001-07-11 | 广东泰禾生物药业有限公司 | Compound (I), extraction process and its application in preparing medicine to cure acute ischemic cerebrovascular disease |
DE10005275A1 (en) | 2000-02-07 | 2001-08-09 | Bayer Ag | Novel glycoconjugates |
US6593119B2 (en) | 2000-02-29 | 2003-07-15 | Glycodesign, Inc. | Core 2 β-1,6-N-acetylglycosaminyltransferase gene |
WO2001083717A2 (en) | 2000-05-03 | 2001-11-08 | Glycodesign Inc. | Designing modulators for alpha-1, 3 galactosyltransferases based on a structural model |
JP3634238B2 (en) | 2000-05-19 | 2005-03-30 | 本田技研工業株式会社 | Floor shape estimation device for legged mobile robot |
DE60119315T2 (en) | 2000-05-30 | 2006-08-31 | Société des Produits Nestlé S.A. | PRIMARY COMPOSITION CONTAINING A LIPOPHILENE, BIOACTIVE FABRIC |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
WO2002003996A1 (en) * | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
US6451355B1 (en) * | 2000-07-17 | 2002-09-17 | Howard M. Reisner | Composition to treat diabetes |
GB0105613D0 (en) * | 2001-03-07 | 2001-04-25 | Univ Cambridge Tech | Pharmaceutically effective compounds and their use |
EP1316608A4 (en) | 2000-09-01 | 2004-12-29 | Kyowa Hakko Kogyo Kk | Novel polypeptide |
AU2000274550A1 (en) | 2000-09-25 | 2002-04-02 | Ultimate Life Technology Co., Ltd. | Cholesterol in blood-lowering composition and its complex, and method for preparing them |
CN1184229C (en) * | 2000-12-27 | 2005-01-12 | 中国科学院上海药物研究所 | Furost saponine analogue and its separation process and use |
CZ20032902A3 (en) | 2001-04-26 | 2004-01-14 | Bristol-Myers Squibb Company | Pharmaceutical tablet with a high content of active substance |
EP1453386B9 (en) | 2001-11-16 | 2010-06-23 | Brandeis University | Prepared foods containing triglyceride-recrystallized non-esterified phytosterols |
US20030096316A1 (en) * | 2001-11-21 | 2003-05-22 | Ingmar Wester | Use of apolipoprotein B as a single marker for evaluation of the risk or cardiovascular disease |
AUPS036402A0 (en) | 2002-02-07 | 2002-02-28 | Solbec Pharmaceuticals Limited | Rhamnose binding protein |
BG106434A (en) | 2002-02-25 | 2003-09-30 | Благой АЛЕКСИЕВ | Pharmacological subtance |
NZ535200A (en) | 2002-03-14 | 2007-07-27 | Forbes Medi Tech Inc | A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
US20060115574A1 (en) | 2002-05-03 | 2006-06-01 | De Groot Willem A | Food product comprising a phytosterol |
CN1187055C (en) * | 2002-06-21 | 2005-02-02 | 成都地奥制药集团有限公司 | Medicine composition for treating myocardial ischemia, angina pectoris and cardiac infarction |
AUPS329002A0 (en) | 2002-07-01 | 2002-07-18 | Solbec Pharmaceuticals Limited | Glycoalkaloid compositions and various uses thereof |
CN1179941C (en) | 2002-08-14 | 2004-12-15 | 技源科技(中国)有限公司 | Process for extracting 4-hydroxy-isoleucine and by-products including feungreek gum from seed of feungreek |
EP1556062B1 (en) | 2002-08-28 | 2009-12-23 | Lupin Limited | Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity |
EP1556406A1 (en) | 2002-09-25 | 2005-07-27 | Forbes Medi-Tech Inc. | Derivatives comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease |
CN1228344C (en) * | 2002-10-21 | 2005-11-23 | 吉林天药科技股份有限公司 | Method for preparing yam saponin, medicinal preparation and new usage in medication |
JP4222810B2 (en) * | 2002-10-28 | 2009-02-12 | 株式会社 タカマ | Gastric mucosa protective agent |
WO2004048938A2 (en) | 2002-11-26 | 2004-06-10 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
CN1218701C (en) | 2002-12-27 | 2005-09-14 | 成都地奥制药集团有限公司 | Use of spirosterol type steroid saponin in preparing medicine for treating cardio-cerebral vascular disease |
AU2003900194A0 (en) * | 2003-01-15 | 2003-01-30 | Solbec Pharmaceuticals Limited | Methods of modulating il-6 |
BG65737B1 (en) | 2003-01-24 | 2009-09-30 | "Софарма" Ад | Standardized mixture of steroid saponins, method for the preparation and apllication thereof |
US20070275420A1 (en) * | 2003-03-19 | 2007-11-29 | Chikara Ohyama | Method For Detecting Prognosis Of Cancer |
WO2004111196A2 (en) | 2003-06-10 | 2004-12-23 | Seikagaku Kogyo Kabushiki Kaisha Also Trading As Seikagaku Corporation | Mutants of core 2 b-1,6-n-acetylglycosaminyltransferase |
CN1615896A (en) * | 2003-11-12 | 2005-05-18 | 云南省药物研究所 | Medicine for regulating blood fat and treating cardiocerehral disease and preparing method |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20050233013A1 (en) | 2004-03-02 | 2005-10-20 | Lee Steve S | Methods for enhancing the transport of glucose for balancing blood sugar levels |
CN1290509C (en) * | 2004-03-22 | 2006-12-20 | 深圳中药及天然药物研究中心 | New use of saponin compound for treating cardiovascular disease |
CN1680424A (en) * | 2004-04-09 | 2005-10-12 | 中国科学院生态环境研究中心 | Preparation and use for active saponin |
KR100740609B1 (en) * | 2004-06-11 | 2007-07-18 | 주식회사 유니젠 | Composition having ginsenosides for treating or preventing angiostenosis and restenosis |
CN1247202C (en) * | 2004-07-05 | 2006-03-29 | 北京科信必成医药科技发展有限公司 | Dioscin oral disintegration tablet and its preparing method |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
-
2005
- 2005-07-06 GB GBGB0513881.3A patent/GB0513881D0/en not_active Ceased
-
2006
- 2006-07-06 EP EP06755733.0A patent/EP1909802B1/en not_active Not-in-force
- 2006-07-06 JP JP2008519999A patent/JP2009500386A/en active Pending
- 2006-07-06 MX MX2008000256A patent/MX2008000256A/en active IP Right Grant
- 2006-07-06 WO PCT/GB2006/002518 patent/WO2007003957A2/en active Application Filing
- 2006-07-06 EP EP11163563A patent/EP2382980A3/en not_active Ceased
- 2006-07-06 CN CN200680031670.3A patent/CN101252939B/en not_active Expired - Fee Related
- 2006-07-06 EP EP11163561.1A patent/EP2382979B1/en not_active Not-in-force
- 2006-07-06 CA CA002614017A patent/CA2614017A1/en not_active Abandoned
- 2006-07-06 EP EP11163564.5A patent/EP2382981B1/en not_active Not-in-force
- 2006-07-06 AU AU2006264644A patent/AU2006264644B8/en not_active Ceased
- 2006-07-06 US US11/481,256 patent/US7998943B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 US US12/588,606 patent/US20100048495A1/en not_active Abandoned
Patent Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1243129A (en) * | 1915-11-10 | 1917-10-16 | Victor S Bauder | Silo and door therefor. |
US1237583A (en) * | 1916-07-22 | 1917-08-21 | Lucinda Taylor | Letter-folder. |
US1361111A (en) * | 1918-10-26 | 1920-12-07 | Claude L Steele | Water-motor |
US2335436A (en) * | 1940-04-15 | 1943-11-30 | Ampro Corp | Cinematograph |
US5880091A (en) * | 1989-03-08 | 1999-03-09 | The Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
US5958770A (en) * | 1990-01-18 | 1999-09-28 | Cham; Bill Elliot | Glycoalkaloids |
US5104856A (en) * | 1990-11-09 | 1992-04-14 | Uab Research Foundation | Heparan sulfate biosynthesis primers |
US5486510A (en) * | 1991-03-28 | 1996-01-23 | Rooperol (Na) Nv | Method and compositions for modulating or control of immune responses in humans |
US5470879A (en) * | 1992-09-07 | 1995-11-28 | Laboratories Monal | Treatment of non-insulin-dependent diabetes |
US5360733A (en) * | 1992-10-01 | 1994-11-01 | La Jolla Cancer Research Foundation | Human β1-6 n-acetylglucosaminyl transferase |
US5624832A (en) * | 1992-10-01 | 1997-04-29 | La Jolla Cancer Research Foundation | β1 6 N-acetylglucosaminyltransferase, its acceptor molecule, leukosialin, and a method for cloning proteins having enzymatic activity |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US5461879A (en) * | 1994-04-19 | 1995-10-31 | Carrier Corporation | Air conditioner condensate slinger |
US5589832A (en) * | 1994-12-02 | 1996-12-31 | Lucent Technologies Inc. | Low noise non-sampled successive approximation |
US5827884A (en) * | 1995-09-15 | 1998-10-27 | Omp Acquisition Corporation | Skin peel maintenance composition and method |
US5638778A (en) * | 1995-12-06 | 1997-06-17 | James; Robert G. | Opposed piston swash plate engine |
US5965449A (en) * | 1996-07-03 | 1999-10-12 | Forbes Medi-Tech, Inc. | Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders |
US6383514B1 (en) * | 1996-11-28 | 2002-05-07 | Henkel Kommanditgesellschaft Auf Aktien | Use of mixtures of active substances for the production of hypocholesterolemic agents |
US6407085B1 (en) * | 1997-01-16 | 2002-06-18 | Horst Kief | Medicament containing betasitosterol and/or phytosterol/betasitosterol mixtures |
US6042834A (en) * | 1997-01-29 | 2000-03-28 | Baraka; Mohamed Wasif | Herbal composition for diabetes and method of treatment |
US5886029A (en) * | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
US5952393A (en) * | 1998-02-12 | 1999-09-14 | Sorkin, Jr.; Harlan Lee | Composition for reducing serum cholesterol levels |
US20020193317A1 (en) * | 1998-03-26 | 2002-12-19 | Zongqin Xia | Steroidal sapogenins and their derivatives for treating alzheimer's disease |
US6087353A (en) * | 1998-05-15 | 2000-07-11 | Forbes Medi-Tech Inc. | Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like |
US20040033521A1 (en) * | 1999-02-03 | 2004-02-19 | Glycodesign, Inc. | Novel core 2 beta-1, 6-N-acetylglycosaminyltransferas E gene |
US20020098563A1 (en) * | 1999-02-03 | 2002-07-25 | Bozena Korczak | Novel core 2 beta-1,6-N-acetylglycosaminyltransferase gene |
US20030004147A1 (en) * | 1999-03-26 | 2003-01-02 | Paul Barraclough | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
US20040220115A1 (en) * | 1999-04-09 | 2004-11-04 | Cham Bill E | Medicinal compositions and their method of preparation |
US20020156051A1 (en) * | 1999-06-23 | 2002-10-24 | Forbes Medi-Tech Inc. | Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders |
US6635461B1 (en) * | 1999-08-24 | 2003-10-21 | Glycozym Aps | UDP-N-acetylglucosamine: galactose-β1, 3-N-acetylgalactosamine-α-R/(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3 |
US20040203111A1 (en) * | 1999-08-24 | 2004-10-14 | Glycozym Aps | UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
US6998501B1 (en) * | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
US6197832B1 (en) * | 1999-09-14 | 2001-03-06 | Harlan Lee Sorkin, Jr. | Composition for reducing serum cholesterol levels |
US6294157B1 (en) * | 1999-10-14 | 2001-09-25 | L'oreal | Composition containing sapogenin |
US20020016314A1 (en) * | 2000-01-31 | 2002-02-07 | Schersl Endre Markovits | Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides |
US20040049352A1 (en) * | 2000-05-10 | 2004-03-11 | Isabelle Andre | Designing modulators for glycosyltransferases |
US20020018811A1 (en) * | 2000-05-15 | 2002-02-14 | Penteado Roberto Luiz Bruno | Application of phytosteroids(and isomers thereof), folic acid, cyanocobalamine and pyridoxine in dietetic (alimentary) fibers |
US6346267B1 (en) * | 2000-07-07 | 2002-02-12 | Wakunaga Of America Co., Ltd. | Composition and method for treatment of symptoms associated with insufficient estrogen production |
US20030156051A1 (en) * | 2000-09-11 | 2003-08-21 | Broadcom Corporation | Sigma-delta digital-to-analog converter |
US20040038923A1 (en) * | 2000-10-06 | 2004-02-26 | Marth Jamey D. | Blocking inflammation by inhibiting sialylation |
US6933291B2 (en) * | 2000-12-01 | 2005-08-23 | N.V. Nutricia | Cholesterol lowering supplement |
US6787151B2 (en) * | 2001-08-10 | 2004-09-07 | Lipton, Division Of Conopco, Inc. | Composition for lowering blood cholesterol |
US20040249138A1 (en) * | 2001-09-28 | 2004-12-09 | Chris Lawson | Solvent extraction process |
US20030098563A1 (en) * | 2001-11-28 | 2003-05-29 | The Timken Company | Hub assembly with driven hub |
US20060052351A1 (en) * | 2003-02-10 | 2006-03-09 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress |
US20070107292A1 (en) * | 2004-05-10 | 2007-05-17 | Gyro Snipe Ltd. | Retro-reflective aiming means |
US20070254847A1 (en) * | 2004-09-30 | 2007-11-01 | Chengdu Di'ao Pharmaceutical Group Co., Ltd. | Pharmaceutical Composition Containing Steroidal Saponins, the Preparation Method and Use Thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2006264644B2 (en) | 2012-06-21 |
CN101252939B (en) | 2015-03-25 |
EP2382981A2 (en) | 2011-11-02 |
WO2007003957A3 (en) | 2007-05-31 |
EP2382980A2 (en) | 2011-11-02 |
EP1909802B1 (en) | 2014-05-21 |
EP1909802A2 (en) | 2008-04-16 |
AU2006264644A1 (en) | 2007-01-11 |
EP2382981B1 (en) | 2014-10-15 |
JP2009500386A (en) | 2009-01-08 |
CN101252939A (en) | 2008-08-27 |
EP2382979A2 (en) | 2011-11-02 |
GB0513881D0 (en) | 2005-08-10 |
US7998943B2 (en) | 2011-08-16 |
EP2382979A3 (en) | 2011-12-14 |
CA2614017A1 (en) | 2007-01-11 |
US20070010462A1 (en) | 2007-01-11 |
WO2007003957A2 (en) | 2007-01-11 |
AU2006264644B8 (en) | 2012-09-06 |
MX2008000256A (en) | 2008-03-19 |
EP2382981A3 (en) | 2011-12-14 |
EP2382979B1 (en) | 2013-11-13 |
EP2382980A3 (en) | 2011-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8609633B2 (en) | Core 2 GlcNAc-T inhibitors | |
US20100048495A1 (en) | Core 2 GlcNAc-T inhibitors III | |
US20110152209A1 (en) | Core 2 GlcNAc-T Inhibitors | |
US8197794B2 (en) | Core 2 GlcNAc-T inhibitors | |
US20070010460A1 (en) | Multiple sclerosis therapy and diagnosis | |
AU2006264635B2 (en) | Core 2 GlcNAc-T inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |